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Abstract 
Introduction: Prostate Cancer (PC) screening has become a controversial topic both in 
the United States and abroad, stimulating debates surrounding who should and should not 
be screened. United States (USA) population-based studies have established a link 
between race and PC risk, but whether race predicts PC after adjusting for clinical 
characteristics is unclear. In Brazil, where cancer registries are limited, underprivileged 
men have limited access to both education and health care due to geographic barriers. 
Thus, we investigated the association between, educational status, geographic distance 
from screening site to follow-up care facility and non-compliance with having cancer, 
and, risk of low and high-grade PC in men undergoing initial prostate biopsy in equal 
access medical centers in the USA and Brazil.    
 
Materials & Methods:  In our first analysis, we conducted a retrospective record review 
of 887 men (49.1% black, 50.9% white) from the Durham Veterans Affairs Medical 
Center (DVAMC) who underwent initial prostate biopsy between 2001 and 2009.  
Multivariable logistic regression analysis of race and biopsy outcome was conducted 
adjusting for age, body mass index (BMI), number of cores taken, prostate specific 
antigen (PSA), and digital rectal exam (DRE) findings. Multinomial logistic regression 
was used to test the association between black race and PC grade (Gleason <7 vs. ≥7).  
Our second analysis used data from the Barretos Cancer Hospital (BCH) screening study, 
another retrospective record review of 1,561 men who were recommended to prostate 
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biopsy after obtaining an initial screen on the medical mobile units between 2004 and 
2007. Multivariable logistic regression analysis of geographic distance from screening 
site to BCH (km), maximum level of education achieved, and risk of non-compliance was 
performed adjusting for age and calendar year of biopsy. Among those who complied 
with biopsy recommendations and received a biopsy (n=850), multivariable logistic 
regression analyses were conducted to test the association between geographic distance, 
educational achievement and having PC. Of those men with PC, a multinomial logistic 
regression test was used to evaluate the association between geographic distance, 
educational attainment and risk of low and high-grade PC (Gleason <7 vs. ≥7).   
 
Results: In the DVAMC study, Black men were younger at biopsy (median: 61 vs. 65 
years, p<0.001), and had a higher pre-biopsy total PSA (tPSA, median: 6.6 vs. 5.8ng/ml, 
p=0.001) than white men. A total of 499 (56.3%) men had PC on biopsy (245 low-grade; 
254 high-grade). In multivariable analyses, black race was significantly predictive of PC 
overall (odds ratio, [OR]: 1.50, 1.12 – 2.00, p=0.006), and high-grade PC (relative risk 
ratio [RRR]: 1.84, 1.28 – 2.66, p=0.001), but was not significantly associated with low-
grade PC (RRR: 1.29, 0.92 – 1.80, p=0.139). In the BCH studies, non-compliant men 
were older at initial screen (median: 68 vs. 66 years, p<0.001), had a higher tPSA 
(median: 4.90 vs. 4.2 ng/mL, 0<0.001), were less likely to have an abnormal DRE 
(19.5% vs. 33.4%, p<0.001), had less education (low education: illiterate or incomplete 
primary, vs. high education: complete primary, high school or college, 1,402 vs. 159, 
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p=0.14, data not shown) and were more likely to live more than 500km from BCH 
(66.3% vs. 19.6%, p<0.001) when compared to men who complied with biopsy 
recommendations. On crude and multivariable analyses, non-compliance was 
significantly associated with increased distance from screening site to BCH relative to 
traveling less than 250km for care (250-500km: OR: 2.00, 500-1000km: OR: 5.88, >1000 
km: OR: 15.98, p<0.001). On crude and multivariable analysis, increased educational 
attainment relative to being illiterate had a protective association with non-compliance 
(incomplete primary: OR: 0.53, complete primary: OR: 0.33, p<0.001, high school + 
college: OR: 0.87, p=0.64). Of the screened men who were recommended to and had an 
initial biopsy, 320 men had cancer (207 low-grade, 113 high-grade). Stratified by 
educational status, illiterate men were older at biopsy (median: 69 vs. 65 vs. 64 vs. 58 
years, p<0.001), and had a higher tPSA at screening (median: 6.04 vs. 4.47 vs. 4.73 vs. 
4.16, p=0.001). There were no differences, based on education, distance from screen site 
to Barretos (p=0.43), year of screening (p=0.08), number of abnormal DREs (p=0.42) or 
family history of cancer, especially PC (p=0.07). Before biopsy, confirmatory median 
tPSA was 7 (IQR: 4 – 16 ng/mL). With respect to PC on initial biopsy, there was no 
association between distance from screening site to BCH (relative to < 250km) and 
increased education achievement. On multinomial analysis, educational achievement 
showed an association with neither low nor high-grade cancer relative to no cancer. There 
was no association between increased distance and low-grade PC. There was no 
association between traveling 500-1000km (p=0.96) or >1000km (p=0.15) and high-
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grade cancer; however, there was a significant association between traveling 250-500km 
relative to <250km and high-grade PC risk (RRR: 2.44, 95% p=0.04).  
 
Conclusion: In a USA-based equal access health care facility, black race was associated 
with greater risk of PC detection on initial biopsy and of high-grade cancer after adjusting 
for clinical characteristics. In Brazil, where cancer data are limited, education and 
geographic distance from point of screening to care facility are not associated with 
having PC on biopsy or biopsy grade. Distance was, however, significantly associated 
with risk of non-compliance after primary screen. Thus, additional investigation of 
mechanisms linking black race and PC risk and PC aggressiveness is needed.  
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1. Introduction  
1.1. Prostate Cancer 
A slow growing cancer with no symptoms until in its most advanced stages, prostate 
cancer (PC) is the most commonly diagnosed among men in the developed world with a 
steadily increasing burden worldwide.1, 2 While incidence rates increased drastically in 
the early 1990s3, the result of widespread acceptance and use of prostate specific antigen 
(PSA) testing as a mean of cancer detection, the burden of disease is disproportionately 
distributed among developed countries relative to developing.  
1.2. Disease Burden 
The role of cancer in the global sphere is steadily increasing despite rapid declines in 
cancer death rates in developed countries.1 This phenomenon could be the result of 
increased life expectancies4, adoption of economic-based cancer-causing behaviors such 
as poor diet and nutrition5, smoking6, 7, and lifestyle factors such as alcohol consumption 
and physical inactivity8. The apparent increased incidence could also be due to 
overdiagnosis, the result of increased availability and use of screening technologies to 
detect early stage disease.9, 10 While an estimated 30% of cancers are preventable in spite 
of these factors, what is clear is that understanding patterns of disease burden can 
ultimately lead to better strategies for prevention and intervention.11  
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PC incidence rates vary worldwide by almost a factor of 2512, due in part to the 
disproportionate use of the PSA test in areas such as Australia, the US, and Europe, 
though there were substantial differences in PC incidence pre-PSA testing.13  After the 
widespread use of the PSA test in these areas in the 1990s, temporal trends in incidence 
rates rose drastically as more cancers, both indolent and otherwise, were being detected 
with the use of this technology, then quickly declined as the result of advances in 
treatment and management.14 Despite these incidence trends, mortality rates are highest 
among men on African descent in the US and Caribbean, implicating a genetic 
phenomenon in the role of PC-mediated deaths.15-17 Interestingly, while men of African 
descent have higher PC mortality rates, the fact that the highest incidence rates occur in 
westernized countries suggests a multifactorial etiology of PC inclusive of both 
lifestyle/diet and genetics. While it is uncertain what specifically contributes to increased 
risk, likely some combination of the aforementioned plays a role in the development and 
progression of PC. 
 
1.3. Screening 
1.3.1. Prostate Specific Antigen Screening 
Developed in the 1980s to monitor disease progression of men with PC, the PSA test 
measures the amount of protein generated by the prostate in whole blood. Typically 
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elevated in men with PC, benign prostatic hyperplasia, and prostatitis, the PSA test is 
most commonly used in conjunction with DRE screening to detect PC. Measured in units 
of ng/mL, the PSA test lacks the ability to differentiate among PSA increases generated 
from aggressive cancers, indolent cancers that will never progress, and the 
aforementioned benign conditions.  
 
PSA exists in the blood in very low concentrations and requires highly sensitive measures 
to calculate it. Men have a combination of both “free” protein in the blood (fPSA) and 
bound protein. tPSA is defined as the sum of fPSA plus the proportion of it that is bound 
to other complexes. tPSA is typically measured by the PSA test. For men whose tPSA is 
between 2.5 – 4.0ng/mL (i.e. slightly elevated tPSA and suspicious of PC), pfPSA is 
included as a secondary measure of PC risk. Literature has shown that men with lower 
pfPSA, for example <15%, are at higher risk of PC.18-20 The PSA ratio (pfPSA) is 
calculated by the amount of fPSA divided by tPSA.  
 
1.3.2. Digital Rectal Exam Screening 
A digital rectal exam (DRE) is an exam performed by a physician during which two 
digits are inserted into a man’s rectum to examine his prostate. The prostate, a typically 
smooth gland, is then felt for nodules, which indicate abnormal growths on the surface, 
typically of cancer. The most basic way of diagnosing prostate abnormalities, DREs are 
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used worldwide to detect PC despite the fact that most tumors are not localized enough to 
determine PC by touch. This observation indicates that most early stage PCs are missed 
by DRE alone, and that diagnosis requires the use of alternative testing to confirm disease 
presence. Challenges with the DRE exam include low sensitivity, provider differences in 
what constitutes a tumor or not, and the patient’s psychological stress related to the 
exam.21 
 
1.3.3. Prostate Biopsies 
A prostate biopsy is a procedure that removes small tissue segments from a prostate gland 
that is suspicious of cancer. Biopsies are conducted once a subject has undergone PSA 
and DRE screening and are the only way to diagnose or rule out PC after a positive PSA 
test. However, there are risks, such as infection, associated with biopsies.  Lower 
cutpoints for PSA positivity have the trade-off of higher sensitivity for PC but more false 
positives, leading to more biopsies.  
 
The procedure is typically performed transrectally using ultrasound as a guide to identify 
locations to be sampled. Transrectal ultrasounds also provide measurements for prostate 
volume. While the number of biopsy cores taken is not fixed, contemporary biopsy 
schemes recommend taking 12 “cores” – i.e. segments of tissue removed from the 
prostate via needles – per patient relative to older schema, which only took six. Some 
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investigators have suggested that increased numbers of positive prostate biopsies seen in 
contemporary cohorts could be the result of the changes to the biopsy scheme, from 6-8 
cores in the 1990s to the current 12-core system, validating the effectiveness of this 
system-wide change.22 
 
Biopsy outcomes are determined pathologically by the Gleason Score grading system.23 
Gleason scores range from 2 to 10, with higher scores indicating a worse prognosis.  The 
score is given as the sum of two integers describing the grade (differentiation) of the 
tumor specimen.  The first number describes the most common pattern of differentiation 
in the tumor and the second number describes either the next most common pattern or the 
highest grade seen in the specimen. These scores are then integrated into clinical practice 
to determine the best course of treatment action whether it is active surveillance, surgery, 
radiation, hormone or chemotherapy.  
 
1.4. Risk Factors 
Though PC etiology remains unclear, widely accepted risk factors such as increased age, 
PC family history, and PSA levels typically greater than or equal to 4ng/mL, have been 
shown to have be independent predictors of cancer.24,25 Competing risk factors such as 
high body mass index (BMI), poor diet, poor nutrition26 and lack of mechanistic studies 
make it hard to determine exact causes of disease and most men diagnosed eventually die 
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of something else. Currently of debate among practitioners, is the ability to predict 
clinical outcomes of patients for prevention and diagnostic purposes. Several established 
nomograms such as the American Urological Association (AUA) symptom score chart27 
and the Partin Tables28, 29, utilize confirmed PC risk factors to help clinicians evaluate 
whether a patient is at risk or at high-risk for PC at presentation. 
 
1.4.1. Health Disparities 
Health disparities are gaps in quality of care, outcomes, or health status that are often the 
result of measurable inequalities in health care services received or rendered. 
Sociodemographics, economic status, and education are all factors, which can influence 
the abundance of health disparities and no doubt severity of cancer at initial 
presentation.30, 31 Demographically speaking, black men have a lower socioeconomic 
status, less education, and lower-paying jobs than their white counterparts, thus limiting 
their access to health-care and screening facilities and affects PC outcome.32  
 
While generalized health disparities are not just limited to socioeconomic status, race, 
education levels, gender and socio-demographics, though they certainly play a role in 
cancer incidence worldwide. It is no secret that public awareness, investigations focusing 
on lifestyle interventions and cancer outcomes, patient education, and screening 
campaigns are ways to combat the affliction with PC.  
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1.4.2. Race 
Race has been linked with increased PC cancer incidence and mortality.33 Though the 
meaning of race is unclear, it is frequently used in the literature to describe a social 
construct with biological implications.26 To this end, race has been linked with socially-
derived, hierarchical classification systems based on one’s skin pigmentation which 
individuals use to associate themselves culturally, religiously, physically and 
politically.34, 35 Race differs from ethnicity, which refers to groups of people from a 
similar nation-state. Biologically, race refers to one’s distinct ancestry, origins, and 
family history.36 
 
In general, the body of literature that specifically looked at race influencing the outcome 
of prostate biopsies, whether initial or repeat, is mixed. Potts et al, for example, 
investigated the relationship between PSA and race retrospectively over a sixteen-year 
period and found that there was no association between race and cancer outcome. They 
did find, however, that cancer was found more frequently in blacks than whites, though 
the association diminished when controlling for PSA.22 Additional studies by 
Grunkemeier et al and Yanke et al, both prospective studies that employed new modeling 
nomograms, were inconclusive on the topic of race and cancer diagnosis, but validated 
PSA as a useful tool for screening, suggesting that looking at PSA and race together 
could prove to be a predictive tool in diagnostic outcomes.37, 38 The literature suggests 
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that given baseline characteristics race alone may not be a valuable tool for prognostic 
predictions on an individual patient level. The inconsistencies in the crude data compared 
with the adjusted data have resulted in conflicting results: some literature sources say 
race alone could be predictive of outcome, others, only when stratified by effect 
modifiers.39 Therefore, the ability to establish an alternative diagnostic tool that 
incorporates race as the primary focus, which will help clinicians determine, pre-biopsy, 
whether a patient will present with cancer on biopsy, is needed. In order to eliminate race 
as a “health disparity” related to PC incidence, more studies are required to evaluate 
whether race is a predictor of PC on biopsy and the underlying biological cause of the 
differences seen in epidemiological studies focused on health disparities. 
 
1.4.3. Education 
Education is the most commonly used indicator of socioeconomic status used in public 
health studies.40 While a marker for current and future earnings, education represents a 
multifaceted concept, which is hard to measure in empirical, epidemiological studies.41 
More than just how much formal schooling one has received, deriving a definition of 
education as it pertains to health status, health seeking behaviors and health outcomes is 
challenging. Education also must include health literacy and communication, overall 
literacy, and knowledge of health related matters.42 Unfortunately, most studies, when 
including education in models as a representation of socioeconomic status, do not specify 
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which of these components is being measured, therefore understanding the underlying 
relationship between education and socioeconomic status as well as education and health 
outcomes is unclear.40 In order to fully understand which facets of education as a marker 
of socioeconomic status are being discussed, better data with more specific variable, or 
combination thereof, must be included in the research in order to fully understand risk 
outcomes.43, 44  
 
 
1.4.4. Access 
Access to care, one of the pinnacles of health disparities research, encapsulates more than 
whether or not one can receive the right care at the right time for the right health 
condition.45-47 Access to care, inclusive of access to screening for chronic illnesses, can 
refer to whether or not individuals can come into contact with the healthcare system and 
utilize its benefits, physically (i.e. distance to care facilities), financially (i.e. insurance 
status, qualifications for care), and knowingly (i.e. having the ability to make informed 
decisions about their health). Access can also reference whether or not primary care 
gatekeepers are available to help patients maneuver within the system to get the care and 
tests they need with appropriate care providers eligible to provide that care. In general, 
patients with lower socioeconomic status are less likely to come in contact with the health 
care system in general48; specifically, they have less access to primary care providers and 
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specialists, less education to know how to make informed decisions49 and maneuver 
within the system once they do manage to encounter it, and overall worse outcomes.50  
 
1.5. Research Objectives 
The goal of this thesis is to examine the effects of selected health disparity constructs on 
PC risk and aggressiveness among men undergoing initial prostate diagnostic and 
screening procedures. In particular, in an American population where racial disparities 
embody a significant portion of the health disparities encountered on a population-level, 
in our first study we examined the association between race and having cancer on initial 
biopsy, and for men who had cancer, the grade of their tumors at initial biopsy. We hope 
to understand at what diagnostic point a man’s race, a construct which encompasses 
biologic and socioeconomic aspects, plays a role in disease outcome. 
 
Given a lack of general Brazilian PC data, there is even less information available on 
screening and PC specific mortality. Our second study seeks to close the gap by 
providing insight into barriers faced by underprivileged men who seek PC screening as 
measured by socioeconomic constructs and PC outcomes. Therefore, we examined the 
distance between the initial mobile medical unit screening site to BCH, hypothesizing 
that men at greater distance from the hospital are less likely to comply with biopsy 
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recommendations and follow through with biopsy. Furthermore, we hypothesized that 
these men who live farther away would be at an increased risk of having more aggressive 
cancer. In an additional analysis, we examined the association between education and risk 
of noncompliance with recommendations to have a biopsy, having cancer on biopsy and 
cancer aggressiveness.  Thus, through this study we hope to address issues of access to 
health care, and education level as a means to explore and better understand PC 
prevention and diagnosis problems in underserved areas of rural Brazil. 
 
In pursuit of these goals, two populations of men were identified with complete data and 
appropriate baseline clinical characteristics to better understand the effects of these 
constructs in respective developed and developing countries from which they stem. 
Therefore, our approach consisted of the following: 
 
Objective 1: Evaluate the role of race in PC risk and aggressiveness among men 
undergoing initial prostate needle biopsy in an American multiethnic, contemporary, 
equal-access hospital. 
 
Objective 2: Evaluate the roles of educational attainment, distance from screening site to 
follow-up care facility, and their interaction with risk of noncompliance, PC risk and PC 
aggressiveness among men undergoing initial prostate screen and subsequent biopsy in 
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rural and urban municipalities in Southern Brazil. These men were screened off-site on 
medical mobile units in their towns and referred for follow-up at a single-site equal 
access hospital.  
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2. Methods & Study Design 
2.1. Durham VA Study  
2.1.1. Data Collection  
After obtaining institutional review board approval, we conducted a retrospective review 
of 1,277 men who underwent an initial prostate needle biopsy between 2001 and 2009 at 
the DVAMC. Enrollment methods have been described previously51. Participants were 
referred for biopsy through the urology clinics typically due to elevated PSA (> 2.5 
ng/mL) or abnormal DRE findings. Participants who qualified were then encouraged to 
schedule a biopsy. Upon returning for their biopsy, a repeat pre-biopsy PSA test was 
performed to confirm indication. 
 
2.1.2. Study Population 
We excluded 19 men who were missing data on race or whose race was neither black nor 
white. Men missing data on pre-biopsy serum PSA (n=43), DRE (n=127), BMI (n=88), 
total number of biopsy cores (n=112), and Gleason score (n=1) were also excluded from 
analysis, resulting in a study population of 887 subjects (69.5%) available for analysis.  
 
2.1.3. Data Analysis 
From participant records, we extracted age at biopsy (years, continuous), race (self-
report, categorical), BMI (<24.99, 25 – 29.99, 30 – 34.99, > 35 kg/m2, categorical), DRE 
(dichotomous, normal/abnormal), pre-biopsy PSA (continuous, ng/mL), prostate volume 
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(continuous, cm3), year of biopsy (continuous, 1994-2009, years), total number of biopsy 
cores (continuous, range 1 – 24 cores), total number of biopsy cores that were positive for 
cancer (continuous, range 0 – 15 cores), and biopsy findings (benign vs. cancer, and 
Gleason score, if cancer positive).  
 
Race, our primary exposure variable, was based on self-report. From the unrestricted 
dataset (n=1,277), men identified as 1=black (n=614, 48.1%), 2=white (n=644 50.4%), 
3=Asian (n=0, 0%), 4=Hispanic (n=2, 0.2%), 5=other (n=9, 0.7%) or had race data 
missing (n=8, 0.6%). Due to small numbers in the other racial groups, we restricted our 
analysis to include only black and white men. As no ancestral marker data was available 
to confirm racial identity, we assigned the men to their respective racial groups based 
upon their primary classification.  In this case, race was converted from a five-level 
categorical variable, to a dichotomous variable called “black1” coded as 1=black, 
0=white. Analyses inclusive of all racial groups did not materially change the strength of 
the association of race as a predictor of PC on initial biopsy; therefore, excluding the 
other racial groups did not have a strong effect on our data and subsequent outcomes.  
 
Pre-biopsy PSA, which was extracted directly from patient records, was evaluated in 
models after being logarithmically-transformed. As this study was recruited on a rolling 
basis, there are no data available for the amount of time that lapsed between the initial 
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abnormal prostate screen via PSA test (and what those values were) and the pre-biopsy 
PSA test that was administered the same day patients received their biopsy. As the PSA 
range from patients included in this study was from 0.30 – 342.6 ng/mL, we evaluated the 
variance, skewness and kurtosis of the data to determine if it was normally distributed 
based on the wide variety observed. We determined, based on these values (variance: 
27,751.79; skewness: 15.93; kurtosis: 287.47) that our variable was not normally 
distributed and therefore required logarithmic transformation before inclusion in our 
models. Unfortunately, there is no clinical use for “logpsa”, therefore, values for baseline 
clinical characteristics were determined prior to changing our variable and only used in 
models evaluating risk of cancer and risk of cancer grade. For these analyses, we did not 
include measures of PSA in our models because PSA is used to detect PC and therefore is 
intricately linked with PC risk. 
 
Participants’ BMIs (kg/m2) were calculated from height and weight measurements 
obtained at the time of biopsy and abstracted from medical records. On a population 
level, black men are more likely to have higher rates of obesity and obesity-mediated 
illnesses than white men.52, 53 With respect to PC, BMI is a known risk factor as studies 
have linked increased BMI with increased PC risk.54 This increased PC risk could be due 
to hemodilution55, a phenomenon wherein more obese men have lower PSA readings at 
diagnosis due to blood volume dilution, therefore, increasing risk of delayed detection 
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and decreasing risk of early detection, resulting in more aggressive cancer when actually 
diagnosed, or having a smaller prostate gland.56, 57 For our data, we elected to evaluate 
BMI categorically based on classifications used in clinical practice rather than as a 
continuous variable as there is no evidence that for every unit of BMI increase, there is an 
equivalent change in risk of PC.  
 
In this dataset, DRE was coded dichotomously as 0=normal, 1=abnormal from data 
pulled directly from patient records. For our analyses, we were interested in the subset of 
men whose DRE was “abnormal”, a predictor and indicator of PC and PC risk. One 
potential issue with DRE in PC detection pertains to evaluating who has a normal vs. 
abnormal DRE. DREs are subjective and are subject to provider opinion, having a 
positive predictive value of 8.8%58. Different providers may evaluate men differently and 
have different thresholds for characterizing a DRE as abnormal. One way to verify DRE 
accuracy is by using transrectal ultrasound, however only a small portion of men in our 
study received these measures of prostate volume, and this measure was not included in 
analysis. 
 
Data for the total number of cores taken at biopsy and the total number of cores positive 
for cancer were derived directly from pathology reports included in patient medical 
records. Additional classifiers, such as percent of each positive biopsy core that had 
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cancer, were also available for evaluation. We elected not to use percent cancer in our 
analysis due to collinearity with total number of cores positive for cancer (correlation 
coefficient, r=0.98, p<0.001) and lack of epidemiological relevance. Furthermore, as the 
average number of cores obtained increased steadily over the total timeframe from which 
the entire dataset – inclusive of our subset – was collected (1994 – 2009), we did not 
include the year of biopsy in our multivariable model due to collinearity with total 
number of biopsy cores (correlation coefficient, r=0.59, p<0.001). We evaluated total 
number of cores and total number of cores positive continuously given clinical standards 
to take approximately twelve cores per biopsy patient, a change that occurred from 
sextant biopsy standards around 2001.  To standardize our analyses, we evaluated only 
men who received biopsies between 2001 and 2009 to ensure that there were no 
differences in the risk of cancer between men who received a sextant-core biopsy, and 
those who received a twelve-core biopsy.  
 
Given that larger prostate glands produce larger quantities of PSA in both benign and 
malignant prostates, studies have shown that prostate volume is a known predictor of PC 
risk when the PSA test is used in screening as cancer causes increased production of 
PSA.59 While the argument could be made that prostate volume is on the causal pathway 
for PC detection, because benign prostatic hyperplasia and prostatitis are also clinical 
conditions in which cancer is not present and increased PSA levels are obtained, there is 
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no definitive link between prostate volume and PC alone. Clinically, men with smaller 
prostates who are at risk of cancer have a higher likelihood of having cancer detected on 
biopsy.60 Conversely, men with larger prostates are more likely to have some of their 
cancer missed on biopsy, resulting in fewer positive cores and a skewed view of their 
cancer grade.61 As such, we elected to investigate models that both included and excluded 
controlling for prostate volume. Subanalyses for men including prostate volume and 
complete data were performed to evaluate the role of PC risk in our models. Though at 
baseline, black men were found to have smaller prostates than white men (data not 
shown), the addition of prostate volume in our model did not materially change the 
strength of the association between black race and PC risk. Unfortunately, complete data 
including prostate volume were unavailable for the majority of men (n=456, 51.4%) and 
therefore was not included in the final analyses. 
 
Our primary and secondary outcomes were cancer risk on initial biopsy and cancer grade. 
Cancer risk on initial biopsy was derived from medical record pathology reports, which 
indicated whether or not patients had cancer on their initial biopsies. Cancer grade was 
defined as no cancer (reference group), low-to-intermediate risk cancer (Gleason Score 
<7) and, high-risk cancer (Gleason Score > 7).62  
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2.1.4. Statistical Design 
Continuous baseline clinical and demographic characteristics (age, year of biopsy, total 
number of biopsy cores, prostate volume, pre-biopsy PSA) were compared between black 
and white men using the Wilcoxon rank-sum test. Categorical variables such as DRE 
(normal/abnormal) and BMI (<25, 25–29.9, 30–34.9, and ≥35 kg/m2) were compared 
using the chi-squared test. 
 
We evaluated the risk of PC diagnosis by race using both crude and multivariable logistic 
regression models (effect measure estimates odds ratios [OR]). In secondary analysis, we 
assessed the association between race and cancer grade (low-grade Gleason <7 vs. no-
cancer, high-grade Gleason >7 vs. no-cancer)62 using a multinomial logistic regression 
analysis to accommodate the three levels of the outcome variable (estimates relative risk 
ratios [RRR] not OR). In both cases, multivariable analyses were adjusted for age, BMI, 
total number of cores, PSA (logarithmically-transformed), and DRE. Although our 
preference was to report RRR and not a combination of OR and RRR to maintain 
conformity amongst our results, adjusted binary generalized models used to estimate 
RRR did not converge, thus two effect measures are reported. 
 
To determine whether or not there were changes in the association between race and 
cancer risk and grade and restricting our cohort based on biopsy scheme changes, we 
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evaluated models, which restricted the years of biopsy to 2001 through 2009 and the full 
cohort, 1994 through 2009. In these models, we also looked at controlling for PC risk 
predictors PSA and DRE. While adding the covariables PSA and DRE to the models did 
have an impact on the association between race and cancer grade and cancer risk, 
restricting the analyses based on biopsy year did not. Given the changes in biopsy 
schema, we therefore elected to evaluate the subset of men who were more likely to 
receive twelve-core biopsies than those of the previous sextant era given the increased 
likelihood to detect cancer and given that six-core biopsies are no longer used in practice. 
We also elected to remove PSA and DRE adjustments from analysis because they 
cofounded the relationship between race and cancer as they are used in cancer detection 
and those with higher PSAs and abnormal DREs are most likely to have cancer on 
biopsy. 
 
All statistical analyses were performed using Stata 12.1 (StataCorp, College Station, TX, 
USA). Two-tailed p-values of <0.05 were considered statistically significant. 
 
2.2. Barretos Cancer Hospital Screening Study 
2.2.1. Data Collection 
After obtaining institutional review board approval, we conducted a retrospective review 
of 17,573 medical records from men undergoing initial PC screening from 2004 to 2007 
in 231 underprivileged cities in Southern Brazil. 54, 55 PC screening took place on medical 
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mobile units based out of BCH. Screening location was targeted to a specific geographic 
region in which the cities tended to be of low socioeconomic status. Specific enrollment 
methods have been described previously.63, 64 Study participants received PC screens 
from mobile medical unit personnel by on-site prostate specific antigen (PSA) testing and 
digital rectal exams (DRE). Men with an elevated total PSA (tPSA) over 4.0ng/mL, tPSA 
between 2.5 – 4.0ng/mL with percent-free PSA (pfPSA) <15%, or with a DRE suspicious 
of PC, were contacted by mail or phone and referred to BCH for follow-up. Once at 
BCH, indications were confirmed with another PSA test and an additional DRE. Men 
whose indications were confirmed were referred for biopsy though we do not have data 
for the amount of time between the date of the initial screen and when the men presented 
to BCH for follow-up testing and biopsy.  
 
2.2.2. Study Population 
We excluded men who had previously been screened, biopsied or who had cancer 
(n=6,456) and men who were missing data on education (n=6) or PSA (n=644), leaving a 
resultant population of 10,467 (60%) men. Of these 1,561 (9%) men were referred for 
biopsy and 1,131 (73%) complied with the recommendation and 430 (27%) did not 
comply. Reasons for noncompliance include men not attending the initial screen (n=375), 
attrition (n=43), they elected to be followed by a primary care physician (n=5), they 
refused to proceed with biopsy (n=6), or for other reasons not specified (n=1). Of the 
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1,131 men recommended to have a biopsy who complied, 273 men were excluded from 
analysis because they did not have a biopsy upon reporting to BCH as requested. Reasons 
for not having a biopsy include a change in biopsy indication upon reporting to BCH 
(n=81), they presented for biopsy outside of the screening interval (n=60), they had a 
PSA too low to be suspicious of PC (n=131), or they were waiting for the procedure 
(n=1). Further, 8 additional men were excluded from analysis due to missing Gleason 
score or pathological clinical stage post-biopsy. Therefore, for secondary and tertiary 
analyses evaluating cancer on biopsy and cancer grade, respectively, 850 (5%) men were 
included for analysis.  
 
2.2.3. Data Analysis 
Among all screened men, we extracted age at screening (continuous, years), tPSA 
(continuous, ng/mL) at screen, distance from screening site to BCH (categorical, <250, 
250-500, 500-1000, > 1000 km), maximum level of educational achievement attained, 
family history of PC (dichotomous, yes/no), family history of any cancer (dichotomous, 
yes/no), calendar year of screening (categorical, 2004, 2005, 2006, 2007), DRE findings 
(dichotomous, normal/abnormal), and biopsy criteria from medical mobile unit patient 
medical records. These records were forwarded to BCH for men recommended to biopsy 
where their PSA and DREs were repeated prior to biopsy for confirmation of screening 
findings. Of the men who received biopsies, in addition to the aforementioned data, we 
also extracted cancer grade using Gleason score (categorical, low-grade=2-6, 
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intermediate=7, high-grade=8-10), pathological clinical stage at biopsy (categorical, 
Stages 1-4), total number of biopsy cores taken (continuous, range 10 – 14), total number 
of positive biopsy cores (continuous), prostate volume (continuous, cm3), tPSA at biopsy 
(continuous, ng/mL), biopsy findings (categorical, benign vs. low/intermediate-grade 
cancer vs. high-grade cancer) and transrectal ultrasound results (TRUS, categorical, 
normal, hyperechoic nodules or hypoechoic nodules).  
 
Age was collected from medical records based on patient report at the time of screening. 
We evaluated age continuously as the data were normally distributed. For the full dataset 
(n=17,573), the age range was 45 – 98 years. For the subset of men included in 
compliance analysis (n=1,561), the age range was 45 – 92 years for those who complied 
to biopsy recommendations (n=1,131), and 45 – 94 years for those who did not (n=430). 
Of the men who had a biopsy (n=850), the age range was 45 – 92 years, as well. Given 
the established relationship between age and PC incidence, we decided to capture both 
the full spectrum of the age-PC relationship (unrestricted), as well as examine any 
differences that may be seen by mimicking the subset of men who would be most likely 
to be screened here in the US (restricted). To capture the most number of men in the 
restricted dataset, we evaluated men 50 – 82 years old. We selected 82 years as the upper 
limit to be inclusive of the majority of men. Thus, we evaluated crude and multivariable 
models of cancer on biopsy and cancer grade using restricted (50 – 82 years, n=829, data 
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not shown) and unrestricted age ranges (45 – 92 years, n=850) and determined that in this 
data set, there were no differences in the model outputs by using restricted or unrestricted 
age as a covariable. 
  
DRE status and PSA were used as the main diagnostic predictors of PC in this cohort. 
DRE status was evaluated based on biopsy criteria and DRE findings. A combination 
dichotomous new variable was created to assess whether the DRE was truly suspicious of 
PC or not. We elected to use pfPSA, tPSA and fPSA measures to justify recommendation 
to biopsy for men presenting for screening based on PSA findings in our cohort. For 
associations between non-compliance and PSA, we logarithmically-transformed the 
values for tPSA to obtain a normally distributed continuous variable for analysis. 
 
Educational status, one of our predictors of compliance, cancer on biopsy and cancer 
grade, was coded as a five-tiered categorical variable as follows: illiterate, incomplete 
primary school, complete primary school, high school and college. Only six men in the 
entire cohort were missing data on education. When evaluating men who had received a 
biopsy, we combined the two highest education categories, high school and college, into 
one because of the small number of men in these groups. This new category was 
indicated “high school + college” and was used in the models that examined the 
relationship between education and having cancer on initial biopsy. On tertiary analysis 
    
  
25  
looking at cancer grade, the small sample size of the higher education group prohibited 
analyses to be completed in the high-grade cancer groups, also a result of small sample 
size of this group. To account for this fact, a dichotomous variable stratifying educational 
status based on low (illiterate and incomplete primary school) and high (complete 
primary school, high school and college) educational attainment was created and used to 
evaluate the association between educational attainment and cancer grade. Additionally, 
to evaluate the interaction between education and distance on cancer risk and cancer 
grade, a new variable, educ*dist, was generated as the cross product of the five-level 
categorical education variable multiplied by the categorical distance variable. This 
interaction term was used to evaluate the relationship that distance and education have 
collectively on cancer risk and cancer grade among men undergoing initial prostate 
biopsy. 
  
Compliance, our primary outcome measure, was evaluated based on whether or not men 
adhered to their recommendation. We based the coding of this variable on whether or not 
the men were recommended to biopsy and whether or not their biopsy was cancelled. 
Biopsies could be cancelled for the following reasons: (1) presented for biopsy outside 
the screening interval; (2) lost to follow up; (3) recommended to be followed through a 
primary care center; (4) refusal of biopsy; (5) biopsy indication was changed at BCH; (6) 
PSA was too low to be suspicious of PC; (7) awaiting the biopsy procedure.  Thus, 
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compliance was defined as: compliant = 3, 5, 6, 7, and non-compliant = 1, 2, 4. 
Associations between predictors of compliance and compliance between those men who 
complied and those who didn’t were evaluated using rank-sum test for categorical 
variables and chi-squared test for continuous variables.  
  
Our secondary and tertiary outcomes, cancer risk on initial biopsy and cancer grade, were 
evaluated using two cancer outcome variables. Cancer risk on initial biopsy was derived 
from medical record pathology reports, which indicated whether or not patients had 
cancer on their initial biopsies. Cancer grade, the tertiary outcome, was defined as no 
cancer (reference group), low-to-intermediate risk cancer (Gleason Score <7) and, high-
risk cancer (Gleason Score > 7).62  
 
2.2.4. Statistical Analysis 
Categorical baseline clinical and demographic characteristics such as distance, 
educational status, calendar year of screening, family history of any cancer, family 
history of PC, and DRE suspicious of PC (yes/no) were compared using the chi-squared 
test. Continuous variables such as age and tPSA were compared using the Wilcoxon 
rank-sum test. These comparisons were evaluated among all men who presented for 
initial PC screen. Additionally, we stratified these men based on each evaluation time-
point of recommendation status and compliance (all screened men, men who were 
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recommended for biopsy, men who were recommended for biopsy and complied with 
their biopsy recommendation, men who were recommended for biopsy and did not 
comply with the recommendation, and men who had a biopsy). We used a chi-squared 
test to determine the differences between men who complied to biopsy recommendations 
and those who did not to determine differences among risk factors for compliance to 
biopsy recommendations.  
 
To evaluate characteristics of the men who received a biopsy, we performed a secondary 
analysis of baseline clinical characteristics and demographics stratified by educational 
attainment. Continuous clinical characteristics age and tPSA were evaluated using 
analysis of variance test (ANOVA) across the four educational categories. Categorical 
variables distance, calendar year of screening, DRE status, family history of any cancer, 
and family history of PC were compared using the chi-squared test. Similarly, to describe 
cancer outcomes of those men who received biopsy at BCH, clinical descriptive statistics 
such as cancer status, Gleason score, clinical stage, TRUS findings, total number of cores 
taken at biopsy, total number of cores that were positive for cancer taken at biopsy, 
prostate volume, and tPSA at biopsy results were examined.   
  
We evaluated the risk of non-compliance to biopsy recommendations and PC diagnosis 
on initial screen by educational status, distance to BCH, and the interaction between 
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education and distance using both crude and multivariable logistic regression models 
(effect measure estimates odds ratios [OR]). On secondary analysis, we assessed the 
association between educational status, distance to BCH and cancer grade (low-grade 
Gleason <7 vs. no cancer, high-grade Gleason >7 vs. no cancer) using a multinomial 
logistic regression model to accommodate the tri-level outcome variable. In this case, the 
model used estimates of relative risk ratios [RRR] not ORs. The final models were built 
by singular addition of selected outcome predictors sequentially from the unadjusted 
model to the multivariable model using forward stepwise addition.  Assessments of 
which variables to include in the final models were based on the fewest required 
adjustments to the model. This decision was made considering the amount of change in 
effect measures from the crude model to final model and its associated p-values. As 
indicated, refined models include an adjustment for the interaction term. Final 
multivariable models have dropped this term out based on associated p-value findings of 
the interaction term in the refined models. Additionally, in multivariable models 
associated with cancer risk or cancer grade, we elected not to adjust for tPSA, DRE or 
prostate volume because these variables are diagnostic indicators of PC, potential 
confounders, and reside on the causal pathway predicting risk. All statistical analyses 
were performed using Stata 12.1 (StataCorp, College Station, TX, USA). Two-tailed p-
values of <0.05 were considered statistically significant. 
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3. Durham VA Study: Race & Prostate Cancer Risk on Initial 
Biopsy (Manuscript 1) 
3.1. Introduction 
In Western society, PC is the most frequently diagnosed non-skin malignancy in men, 
with black men twice as likely to die from PC as white men.12 The increased risk of 
aggressive disease could be due to increased risk of having cancer on biopsy, higher risk 
of aggressive disease at diagnosis, poorer outcomes after treatment, or a combination 
thereof. 
 
Regarding outcomes after treatment, the data are mixed as to whether race is correlated 
with poor outcomes.65-67 However, a key question is whether adjusting for stage, grade, 
and other clinical parameters (i.e. “all else being equal”) can explain the worse outcomes 
in black men. One approach to accomplishing this uses data from an equal access medical 
center, wherein differences in access to care are minimized and detailed clinical 
characteristics are available and can be accounted for. We have previously shown in an 
equal access setting that black men are more likely to have a prostate-specific antigen 
(PSA) recurrence after radical prostatectomy even after controlling for clinical 
characteristics68, supporting the hypothesis that black race is linked with PC 
aggressiveness.  
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There are two possible non-mutually exclusive ways that black men could have more 
aggressive disease: increased risk of having cancer on biopsy (i.e. higher incidence) or 
increased risk of aggressiveness of the cancer. While on a population level, black men do 
have increased PC incidence, this does not address the “all else being equal” (i.e. 
controlling for confounders). In contrast to the consistent population level data showing 
increased PC incidence in black men, individual studies show mixed results as to whether 
black race is a risk factor for PC at the time of biopsy.69, 70 Similarly, studies examining 
the aggressiveness of the cancer as a function of race have been inconclusive.71, 72 
 
We examined the association between black race and biopsy outcomes in men 
undergoing initial prostate biopsy at the DVAMC. We hypothesized that black race is 
associated with PC aggressiveness and postulated that when all else is equal, black race 
will be associated with increased PC risk and disease severity.  
 
3.2. Results 
3.2.1. Baseline Clinical Characteristics 
There were similar proportions of black (n=431, 48.6%) and white men (n=456, 51.4%) 
in this cohort. Black men were younger at biopsy (median age: 61 vs. 65, p<0.001, Table 
1) and had higher pre-biopsy PSA values (6.6 vs. 5.8 ng/ml, p=0.001).  A smaller 
proportion of black men had abnormal DRE findings than white men (25.3% vs. 30.9%, 
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p=0.06), though the difference was not statistically significant. There were no differences 
between black and white men in BMI (p=0.32), total number of biopsy cores (p=0.84), or 
year of biopsy (p=0.29). 
 
In our data set, among men under 55 years old (n=115), 81 (70.4%) were black, and 34 
(29.6%) were white. In this subset, black men still had higher pre-biopsy PSA (black, 
median [IQR]: 5.5 [4.4–8.5]; white, 5.1 [3.1–6.6]) than their white counterparts. 
 
3.2.2. Biopsy Outcomes 
Of the 887 men, 499 had cancer on biopsy (56.3%, Table 2).  Black men (61.9%) were 
significantly more likely to have cancer on biopsy than white men (50.9%, p=0.001). 
Among men with cancer, there was no significant evidence that black men had more 
positive cores than white men (p=0.08). Of the men with a positive biopsy, high-grade 
PC was more common in black men than in white men (54.3% vs. 46.9%), although the 
difference was not statistically significant (p=0.10).   
 
In our data set, among men under 55 years old, a greater proportion of black men still had 
cancer (black 60.5% vs. white 47.1%) though there were no differences in the clinical 
characteristics among men with cancer between blacks and white (p=0.12 for PSA, 
p=0.17 for biopsy outcomes).  
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To evaluate whether our results were confounded by prostate volume, we examined a 
subset of men with available prostate volume data (n=489, 49%).  Among men in this 
subset similar to the entire cohort, race was significantly related to PC risk on 
multivariable analysis (OR 1.48, 95% CI 0.99 – 2.20, p=0.058). The addition of prostate 
volume to the multivariable model did not materially change the strength of the 
association between race and biopsy.  
 
3.2.3. Crude Associations Between Race and Cancer 
On crude analysis, black race was associated with a significantly increased risk of PC on 
biopsy (OR: 1.57, 95%CI: 1.20–2.05, Table 3). When stratified by grade, on crude 
analysis, black race was more strongly linked to high-grade (RRR: 1.82, p<0.001) than 
low-grade PC (RRR: 1.35, p=0.06, Table 3), as compared to the ‘no cancer’ category.   
 
3.2.4. Adjusted Associations Between Race and Cancer  
The association between black race and risk of PC on biopsy changed minimally after 
adjusting for age, total number of cores, BMI, DRE and PSA (OR: 1.50, 95%CI: 1.12–
2.00, Table 3). After multivariable adjustment, race was not significantly associated with 
low-grade PC (RRR: 1.29, p=0.14), but remained significantly associated with high-
grade PC (RRR: 1.84, p=0.001, Figures 1,2).  
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In our dataset, among men under 55 years old, multivariable logistic regressions for 
cancer on biopsy (OR: 1.44, 95%CI: 0.62–3.37, p=0.40), and multivariable multinomial 
logistic regression analyses (relative to no cancer, low-grade: RRR: 1.23, 95%CI: 0.47–
3.21, p=0.676, high-grade: RRR: 1.99, 95%CI: 0.60–6.59, p=0.261) suggested positive 
associations between race and cancer, and race and cancer grade in this subset, though the 
associations were not statistically significant. 
 
3.3. Discussion 
Accounting for almost 10% of cancer deaths in American men, PC remains the most 
prevalent form of cancer in men with an estimated 238,590 new cases diagnosed in 
2013.73 This burden is highest among black men. Whether this can be explained by 
inadequate access to care remains unclear. As such, our key finding that in an equal 
access setting with analyses adjusted for baseline clinical characteristics, black men have 
an increased risk of PC on initial biopsy, specifically high-grade PC, supports the 
hypothesis that black race is inherently linked with more aggressive PC.  
 
Overall data on whether race predicts PC after adjusting for clinical characteristics are 
mixed. The magnitude of the positive association between black race and increased PC 
risk (50% increased risk) is consistent with that of population-level findings from both 
SEER (67% increased risk) and the Prostate Cancer Prevention Trial (40% increased 
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risk).12, 74 Although the association between black race and increased PC risk is well-
documented, several studies found that race is not a predictor of PC risk in populations on 
repeat biopsy,75, 76 or in men who had fewer than 12-biopsy cores taken70. Such findings 
suggest that selection bias may have an effect on PC risk in these populations. 
Furthermore, one study found that race was not associated with increased PC risk when 
adjusting for socioeconomic status and literacy. However, the study may have lacked 
power to detect a significant association due to a small sample size (n=212).77 
Collectively, while these studies all suggest that race is not an independent predictor of 
PC risk, none also looked at the association between race and PC grade or controlled for 
other factors that may influence risk on initial biopsy.  
 
To our knowledge, our study is the first conducted in a contemporary cohort to confirm 
that black race is an independent predictor of total and high-grade PC on initial biopsy. 
Yanke et al, for example, examined race as a predictor of cancer on initial biopsy with a 
cohort of almost 10,000 men from three different equal access care centers; however, 
they did not include analyses evaluating cancer grade as an outcome of their 
predictions.69 Our results are consistent with their findings. While results from this study 
support the idea that black men should be targeted more aggressively for initial PC early 
detection efforts, one notable feature of our cohort is that the DVAMC is an equal access 
hospital, which minimizes the effects of access to care issues. Therefore, by making 
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everything equal to the extent possible in our study, the fact that black men were still at 
an increased risk for PC overall and, specifically for high-grade PC, points to a need for 
additional studies aimed at understanding the molecular underpinnings for this 
phenomenon. Likewise, it suggests that more rigorous screening for PC in black men 
could be beneficial.  
 
While there has always been controversy surrounding the benefits and risks of PSA 
screening, this has intensified recently with the publication of the U.S. Preventive 
Services Task Force (USPSTF) guidelines on PSA screening and the American 
Urological Association (AUA) guidelines on PC screening.  Specifically, the USPSTF 
suggests the risks of PSA screening outweighs the harms78, while the AUA suggests 
shared decision making, but only for men between the age of 55 and 69.79 Notably, the 
AUA guidelines discuss recommendations for men at “average risk” of PC. However, 
based upon the current data and those of others, it is clear that black men are not average: 
they have greater than average risk. As such, what policy should be developed for 
screening within a group that is clearly at high-risk for aggressive PC and PC death? 
 
While one could argue that such a group is in most need of screening and early detection, 
a counter argument could be made that given the inherent aggressiveness of PC in black 
men, that screening would be unable to overcome this.  In support of the former 
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argument, it should be noted that during the PSA era, PC deaths declined to a greater 
extent in black men than white men73. As such, this provides circumstantial evidence that 
screening is beneficial for black men. Indeed, the goal of screening is to identify men at 
greatest risk of PC death who in theory stand the most to benefit. The current data 
suggest that black men represent such a group. Therefore, if further studies support our 
findings that even at initial diagnosis, black men present at younger age and with more 
aggressive disease, this would strongly support targeted screening approaches for all men 
of African ancestry – even below the AUA guidelines age limits of 55.  
 
In our analysis of men younger than 55 years, there were a larger number of black men, 
they had higher PSA levels, and, relative to white men, had more aggressive cancers. 
While an association between race and cancer on biopsy and race and cancer grade is 
evident, there were no statistically significant associations in these models, which could 
be the result of small numbers and low power within men in this subset with complete 
data from our dataset. Thus, while this subset analysis does not show that early and 
aggressive screening helps black men it still provides evidence that, in conjunction with 
population-level data, screening younger black men will identify more cancers at an 
earlier stage, which is a pre-requisite for screening to improve outcomes. 
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As with any retrospective study, there are limitations regarding the outcomes reported 
and generalizability investigated here. With respect to our population, our cohort is not 
representative of the general U.S. population as we are analyzing data from veterans 
using an equal access facility. Because we had access to data from a single equal access 
facility, our sample size is relatively small.  Additionally, exclusions are high, as the data 
were not uniformly collected for all patients, though similar trends were noted in men 
who did not have complete data available for analysis. Even though zip codes are 
recorded in medical records, we did not have complete data available and were unable to 
separate the effects of race from socioeconomic status. Some data suggest that even when 
controlling for socioeconomic factors, black race remains an independent predictor of 
disease recurrence and/or cancer mortality80. Furthermore, family history data was not 
available for men included in this cohort. Of significance is that in this study, race was 
self-reported, given the heterogeneity of ancestral marks among self-reported blacks. As 
a result, important social and cultural structures may not be controlled for or measured 
that influence results. Future studies should examine the combination of ancestral 
markers, genetic mapping, and ethnicity to determine the exact relationship between 
genetic racial identification, social racial identification, and adherence to cultural norms 
with respect to cancer predictability on biopsy. Given that genetics only accounts for 
approximately 5- 42%81 of the biological differences between races, it is clear we need to 
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develop a better understanding of the non-genetic drivers of racial differences as it relates 
to PC risk.  
 
A strength of this study is that DVAMC is an equal access facility which should 
minimize health care access issues among those qualified to receive care at this facility.82 
Additionally, though also described as a limitation, in this context, self-reported race 
lends insight into the cultural and social indices that people use to self-identify and 
provides valuable insight beyond mere genetics. It is clear that race is not the biological 
classification strata historically represented in research and other studies, thus further 
studies to fully understand the link among black race, PC risk, and PC tumor 
aggressiveness are needed. 
 
3.4. Conclusion 
In an equal access medical center, we found that black race was positively associated 
with an increased risk of overall and high-grade PC risk on initial prostate biopsy even 
after adjusting for key clinical characteristics. This suggests that when all else is equal, 
black men are at a heightened risk for PC, which should be taken into account when 
considering whether to screen black men given current PC screening guidelines are based 
on average risk men.  
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4. Barretos Cancer Hospital Study: Education, Distance, 
Compliance to Biopsy Recommendations & Prostate Cancer 
Risk on Initial Biopsy (Manuscript 2) 
4.1. Introduction 
 
Brazil is the largest country in South America and home to a plethora of population 
groups and diverse environmental regions marked by extreme disparities, both 
socioeconomically and with respect to health-care access.83 Cancer is the third leading 
cause of mortality, accounting for nearly 72% of the chronic, non-communicable disease 
mortalities in 2007.84.85 Among Brazilian men, PC is the most diagnosed cancer with 
incidence rates that are steadily increasing.86 This increased PC burden is likely due to 
increased screening.  
 
Like many underprivilidged areas, screening for PC in Brazil is not without its 
challenges. As a developing country in transition with cancer registries still solidifying, 
data is sparse regarding predictors of cancer, cancer mortality, and cancer outcomes. To 
date, there is very little research on the effects of risk factors, ineffective screening and 
access to health care in these and other Latin American communities with regard to PC. 
A beginning step toward managing what is now finally being recognized as a serious 
public health concern, officials have recognized the significance of the burden of cancer, 
both socially and economically, and are doing what they can to extend as many lives as 
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feasible. The use of a single-site tertiary-care facility to cater to rural and nearby urban 
populations has been proposed to spearhead screening efforts to reach rural populations 
that have limited access to follow-up care. Though from a data perspective this will help 
unify collection efforts, geographic distance from screen site to the centralized hospital 
may prove to be a barrier for men undergoing screens who live far away. These 
challenges with respect to obtaining adequate follow-up, for example, obtaining 
transportation due to a lack of public transit, loss of daily wages, climate barriers, and 
inadequacy of local health facilities, still exists.87, 88 
 
Educational level has been reported to be associated with health outcomes and mortality 
in countries with higher average educational levels.89  Thus, educational achievement 
among men in rural areas may be a barrier to PC screening as well. As men in rural areas 
have less access to higher education, these men are at increased risk of having low overall 
and health literacy levels, and specifically, little knowledge about PC, its symptoms, and 
treatments. Thus, low education is a marker for low socioeconomic status and therefore 
increased risk of health disparities. Though the relationship between literacy levels and 
screening has been examined90, the link between literacy levels and PC-specific outcomes 
has been untested in these populations. As such, the exact relationship, if any, among 
education, geographic distance to care, and compliance with PC risk is unknown. We 
seek to examine whether education is associated with health outcomes and behaviors in a 
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setting where the average educational level is very low, especially relative to US 
educational standards.  
 
We examined the relationship between noncompliance to biopsy recommendations 
among all men recommended to biopsy with educational status and distance from 
screening site to follow-up care center. As a secondary analysis, among all men who 
complied with biopsy recommendations and had a biopsy, we evaluated the association 
between educational status, distance from screening site to follow-up care center and 
biopsy outcomes in men undergoing initial prostate screen and subsequent prostate 
needle biopsy at BCH. We hypothesized that lower educational status, greater distance 
from screening site to follow-up care center, and the interaction thereof would be 
associated with increased risk of noncompliance to biopsy recommendations, overall PC 
risk and disease severity.  
 
4.2. Results 
4.2.1. Baseline Clinical Characteristics 
Non-compliant men (n=430, 27.5%) were older at initial screen (median: 68 vs. 66 years, 
p<0.001), had higher tPSA results (median: 4.90 vs. 4.2 ng/mL, 0<0.001), and were less 
likely to have an abnormal DRE (19.5% vs. 33.4%, p<0.001) when compared to men 
who complied with biopsy recommendations (n=1,131, 72.5%). Socioeconomically, non-
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compliant men had less education (low education: illiterate + incomplete primary vs. high 
education: complete primary + high school + college, 1,402 vs. 159, p=0.14) and were 
more likely to live more than 500km from BCH (66.3% vs. 19.6%, p<0.001). There were 
no differences in family history status for any cancer (p=0.07) or for PC (p=0.15) among 
all men recommended to biopsy (Table 4). 
 
The overall education level of the population of men who presented for biopsy was low. 
Stratified by education, there were fewer men in the higher educational groups, high 
school, college and complete primary school (n=84, 9.8%), than those in the lower 
groups (n=774, 90.2%). Baseline clinical characteristics indicated that illiterate men were 
older at biopsy (p<0.001) and had higher tPSA (p=0.001) than men with incomplete or 
complete primary school and those with high school or college level education. There 
were no differences across educational groups with respect to distance from care site to 
BCH (p=0.43), year of biopsy (p=0.08), having an abnormal DRE (p=0.42), or family 
history of any cancer (p=0.07), especially PC (p=0.07). Men with high school or college 
level education were more likely to live closer to BCH, were younger, had the lowest 
PSA at biopsy, and higher percentage of the population had an abnormal DRE and family 
history of cancer (Table 6). 
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4.2.2. Risk of Non-Compliance 
Our primary analysis, evaluating the risk of non-compliance, was performed in the subset 
of men who were recommended to biopsy at BCH (n=1,561). On crude analysis, non-
compliance was significantly associated with increased distance from screening site to 
BCH relative to traveling distance less than 250km for care (250-500km: OR: 2.00, 95% 
CI: 1.40 – 2.85, 500-1000km: OR: 5.88, 95% CI: 4.07 – 8.51, >1000 km: OR: 15.98, 
95% CI: 11.41 – 22.38, p<0.001, Table 5a). In our second crude analysis, increased 
educational attainment, relative to being illiterate, had an inverse association with non-
compliance (incomplete primary: OR: 0.53, 95% CI: 0.42 – 0.68, complete primary: OR: 
0.33, 95% CI: 0.19 – 0.58, p<0.001, high school + college: OR: 0.87, 95% CI: 0.48 – 
1.56, p=0.64, Table 5b).  
 
The risk of non-compliance by educational status was little changed after multivariable 
adjustment with age and biopsy year for education (Table 5b). The adjusted model, which 
included the interaction term for distance and education and was adjusted for both 
education and distance, indicated that there was no association between risk of non-
compliance and the interaction of distance and education (Table 5c). Finally, the 
association between increased distance and non-compliance was little attenuated by 
multivariable adjustment with age and biopsy year with respect to the crude association 
(Table 5d).  
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4.2.3 Biopsy Outcomes 
Of the 850 men who presented to BCH for a biopsy, 320 (37.7%) had cancer. Of the men 
with a positive biopsy, 65% had low-to-intermediate risk cancer as indicated by their 
Gleason score (Gleason 2 – 6), which was confirmed by pathological clinical staging 
(74.5% of cancers were Stage 1). The median number of cores taken at biopsy was 12 
(IQR: 10 – 14) with the median number of cores that were positive of the total was 3 
(IQR: 2 – 5). Measures of prostate volume (median: 33 cm3, IQR: 25 – 46) were taken as 
well as a repeat tPSA for confirmation (median: 7 ng/mL, IQR: 4 – 16, Table 7) for all 
men.  
 
4.2.4. The Association Between Education, Distance and Cancer on Initial 
Biopsy 
The association between education and distance and having cancer on initial biopsy was 
performed using the subset of men who actually had a biopsy. On crude analysis, there 
was no association between distance from screening site to BCH (relative to < 250km, 
Table 8a) and increased education (Table 8b) with having cancer on biopsy. Adjustment 
for age and the interaction term for education and distance in the refined model (Table 
8c) did little to change the association between education, distance and cancer risk. 
Similar findings were observed in the final multivariable model upon removal of this 
interaction term (Table 8d). 
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4.2.5. Adjusted Associations Between Education, Distance and Cancer Grade 
on Initial Biopsy 
The association between education and distance and cancer grade on initial biopsy was 
performed on the subset of men who had a positive biopsy. On crude analysis, relative to 
no cancer, there was no association between increased distance and low-grade cancer. For 
high-grade cancer, there was no association between the group of men who traveled 500-
1000km (p=0.96) or those who traveled >1000km (p=0.15), however there was a 
significant association with men who traveled 250-500km relative to <250km (RRR: 
2.44, 95% CI: 1.03 – 5.79, p=0.04, Table 9a). Education, categorized as a dichotomous 
variable, on crude analysis showed no association with both low and high-grade cancer 
relative to no cancer (Table 9b). The association between education and cancer grade 
changed little when adjusting for age, biopsy year, the interaction between distance and 
education, and total number of cores taken (Table 9c). Final adjustments to achieve our 
final multivariable model without the interaction term showed the same trend of no 
association between our exposures and our outcome (Table 9d). 
 
4.3. Discussion 
Population-level data surrounding PC incidence, mortality and incidence are limited in 
most Latin America countries, and Brazil in particular. While estimated Brazilian PC 
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incidence rate increases could be due to the increased use of widespread PSA testing 
(79.3 per 100,000 in 2002 and rising)91, these numbers may be an underestimation of true 
incidence rates as they are likely non-inclusive of men living in rural areas with limited 
access to screening and health education about the disease.  
 
In this study among men from a large-scale Brazilian screening cohort, we found that 
increased distance to care facility was significantly associated with increased risk of non-
compliance to biopsy recommendations (2 – 16 times more likely), while lower education 
was significantly associated with a decreased risk of non-compliance.  Though in this 
cohort the risk of high-grade cancer was low – 75% of detected cancers were classified as 
stage one - as predictors of cancer, there was no increased risk of having cancer on initial 
biopsy based on distance or education.  In this case, stage distribution and the lack of 
association with education and distance could be a reflection of the substantial non-
compliance rates. The men that were least compliant were those at greater distance from 
the hospital, with lesser access to health care, therefore, it is possible that the men with 
more advanced disease were less likely to present for biopsy and have their cancer 
confirmed. 
 
With respect to cancer aggressiveness, there was no association between distance and 
low-grade cancer or education and low or high-grade cancer. However, there was an 
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association with high-grade cancer in the subset of men who traveled a moderate distance 
to receive care. Despite these negative results, the risk of high-grade cancer in this cohort 
was low which may have impacted our results.  
 
Education, a marker of socioeconomic status, is widely used in public health studies as it 
is an easy to define metric, generalizable across multiple populations and is easy to 
collect. Furthermore, education can be used as an indicator of health literacy, knowledge 
of healthy lifestyle choices, and more informed health-seeking behaviors. Aside from 
academic achievement, the term education can also mean education about health. Lower 
education is correlated with adverse health outcomes due to limited comprehension of 
health concepts, exposure, and advice. These men may simply not understand the 
information imparted to them. The overall educational level of men in this cohort was 
unevenly distributed with the majority of men having low educational achievement. This 
suggests that the majority of men in our cohort were older as older generations are less 
likely to benefit from educational outreach, have health insurance, and come into contact 
with the health system. Thus we expected to see a correlation between noncompliance to 
biopsy recommendation and lower educational status based on the lack of ability to 
comprehend the importance of attending follow-up visits. Our findings were inconsistent 
with this observation.  
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Additionally, studies have shown that education is a marker for socioeconomic status92 
and that people in rural areas are more likely to have less access to education.93  A study 
by Albano et al examined the effects of education and race on general cancer mortality in 
the US.94 Their cohort of approximately 120 million people from the National Center for 
Health Statistics database examined mortality rates from multiple cancer types (including 
PC) using education level as the sole socioeconomic predictor. They found that among 
men with fewer than twelve complete years of education, the death rate from PC was 
almost double that of their higher education counterparts. A study by Reyes-Ortiz, which 
examined the effects of education and literacy levels among older Latin American adults 
are consistent with this finding.90 An additional study based out of Sao Paolo, Brazil, 
which examined social inequalities among the elderly, indicated that elderly individuals 
with higher educational achievements had an overall lower prevalence of non-
communicable diseases and PC risk factors.95 Our hypothesis, that less education is 
associated with higher PC incidence and aggressiveness has been contradicted by our 
findings. This contradictory finding could be due to low numbers of enrollment of men 
with high educational achievement who live in these rural areas or exclusion based on 
previous screening attempts at different care centers.  
 
Geographic distance to care is a barrier restricting health system access around the world, 
however data evaluating the association of geographic distance to care and cancer 
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outcomes are limited. According to the literature, this is the first study conducted in PC. 
A study by Seal et al in colorectal cancer showed that men who live further away from 
care centers are less incentivized to participate in clinical trials, follow-up exams and 
attend routine provider visits for preventive care.96 An additional study by Katarai in 
2011 found consistent findings.97 However, these studies compared distances of 25 or 50 
miles, as opposed to our study where the distances are greater and the potential 
challenges to get to BCH from the screen site are increased. As the majority of the men in 
our cohort lived within 500km of BCH, we expected to see an increased risk of 
noncompliance to biopsy recommendations, which we did. Our findings were consistent 
with their results. Regarding cancer outcomes, we expected to see a correlation between 
increased distance from care center and more aggressive tumors. Our findings, however, 
did not find a relationship consistent with this hypothesis. The inclusion of the interaction 
term, for example, suggesting that lower education and longer distance would be 
correlated with increased risk of noncompliance, cancer on biopsy and more aggressive 
cancer showed no relationship. These results could be due to low numbers of high-grade 
cancers found in this cohort, low numbers of men with high educational attainment, few 
numbers of men who lived further away, nonparametric distribution of distance data, or a 
combination of the above. 
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Our study has several limitations most important of which is the fact that these data were 
not collected with research intent. Therefore, the potential for information bias is high. As 
a collective part of a cancer outreach screening program64, these men gave their data to 
health care providers in order to receive free recommendations on their cancer risk. This 
could also be a source of concern ethically as these men did not consent for their data to 
be used for research. Additionally, if a screening program is implemented, it’s important 
to have reasonable systems in place to follow up on abnormal findings. Asking men to 
travel many hundreds of miles for follow-up is ethically questionable, especially for a test 
like PSA that has many limitations and problems. Additional studies are needed to 
determine if the risk of PC and PC aggressiveness stratified by socioeconomic status 
holds with more reasonable follow-up guidelines for the men who are recommended to 
biopsy but live very far away. 
 
Despite these limitations, there are several key strengths of this study. Given the high 
level of illiteracy, investigators contacted men whose biopsy indications were suspicious 
of PC by mail or by phone. By including a phone call as a method of notification, it 
insures that the men received the information and were able to understand it. If 
notifications were only by mail, this could be a major explanatory variable for the low 
follow-up rates in the illiterate men. Secondly, contamination issues commonly seen in 
large-scale screening studies were minimized as we restricted analysis only to men who 
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are having a first screen and/or biopsy. This eliminates the biases introduced by repeat 
biopsies and repeat screen attempts. Thirdly, there were standardized methods of data 
collection before and during screening for each enrolled subject. Of the men analyzed, all 
had complete pre-clinical and demographic data recorded in medical records, which were 
included in analysis. Furthermore, the availability of complete data minimizes the effect 
and/or potential for recall bias with respect to cancer outcomes and cancer 
aggressiveness. As all pre-biopsy screens were done offsite, all sample collections and 
DRE exams were administered by the same personnel, therefore ensuring uniformity in 
classification of cancer status, and that all blood samples that were measured for PSA 
were treated the same way. Regarding post-screen biopsies, there was limited variability 
in the number of cores taken per patient recommended to biopsy (median: 12, IQR: 10-
14), which is consistent with worldwide recommendations to take twelve cores per 
prostate to optimize detection of cancer.98 It is clear that despite these strengths, this 
negative study is by no means conclusive or representative of the true relationship among 
education, distance to care, noncompliance and cancer outcomes in an underprivileged, 
developing world setting. Additional studies are needed to fully test the relationship of 
these health disparity indicators with outcomes to fully understand the link between 
socioeconomics and cancer risk.  
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4.4. Conclusion 
In a Brazilian cohort of men undergoing PC screening, we found that educational 
attainment, a social marker for socioeconomic status, was not associated with an 
increased risk of overall PC on initial prostate biopsy even after adjusting for key clinical 
characteristics. Additionally, we found that distance from screening site to follow-up care 
facility, though a risk factor for non-compliance to biopsy recommendations, was also not 
positively associated with risk of PC or cancer grade on initial biopsy. This suggests that 
when all else is equal, only distance is a factor when assessing compliance to PC biopsy 
recommendations, and that additional research into risk factors of cancer and cancer 
grade in underprivileged regions on biopsy are needed.  
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5. Perspectives 
The global burden of cancer is increasing worldwide. Increasing life expectancies as well 
as the number of countries that are in economic transition from lower-middle income to 
middle income has resulted in a marked increase in cancer cases and cancer mortality. 
Thus, cancer has emerged as a forefront global public health priority99. 
 
This thesis provides evidence that socioeconomic health disparities influence PC 
detection on initial biopsy. While other studies have evaluated these indices in other 
cancers and after PC treatment, these studies are evaluating them at the beginning of 
diagnostic timeline. By choosing this time-point, we sought to understand where potential 
interventions could be most useful in preventing PC and minimizing potential risk.   
 
Our studies, which evaluated the role of race, educational status and distance from 
primary screen site to follow-up care facility with cancer status and aggressiveness on 
initial biopsy, provided encouraging results that will not only require additional studies, 
but also shed light on the multifaceted nature of PC. Nonetheless, it is important to 
address the broad implications of these findings, limitations and suggest future directions 
for further investigation.  
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Our US-based study on race and PC risk and aggressiveness on initial biopsy found that 
black race was significantly associated with an overall increased risk of having cancer on 
initial biopsy, especially low-grade cancer. While a strength of this study was that it was 
performed in an equal-access hospital with intention of minimizing access to care and 
socioeconomic confounding100, our data suggest that perhaps the mechanism behind this 
phenomenon is biological.  As such, what needs to be understood is what it is about race 
that makes black men at higher risk when all external things are essentially equal.  
 
Race, in the US, is both a social and a biological construct that encompasses many 
different facets. Socially, race could describe one’s diet, lifestyle, anthropologic and 
cultural choices, whereas biologically, race is defined by ancestral informative markers or 
single nucleotide polymorphisms associated with skin pigmentation.101 Our data was self-
report and collected retrospectively, therefore, we evaluated race as a social construct. 
While this can be viewed as a strength of the study – that men were allowed to classify 
themselves relative to how they best identified – what remains to be seen is if these men 
were classified based on their biological race, would the same patterns of risk be seen.  
 
Because we evaluated race as a social and not biological construct with respect to PC 
risk, we potentially introduced bias into our models and therefore our results. The 
potential for misclassification as a result of data being abstracted from patient medical 
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records is high. We controlled for this by only using men who had complete data 
available for the variables we chose to include. Additionally, to control for potential 
confounding due to PSA, DRE and prostate volume, we evaluated models that included 
and excluded these variables and elected to remove them from our analysis. The potential 
for both selection and information bias also existed within our analyses. As 
aforementioned, the number of biopsy cores taken per patient varies and has increased 
over time from the early 1990s until about 2001. As such, by taking more biopsy cores, a 
provider has an increased likelihood of detecting cancer on initial biopsy relative to 
before when fewer cores were taken. To eliminate the potential for selection bias, we 
elected to evaluate models that controlled for biopsy year over the total number of cores 
taken as with increasing biopsy year increased number of cores were taken up to 2001. 
Finally, the potential for information bias exists in retrospective cohorts, which may 
influence the power of our results. One potential source for information bias lies in the 
fact that we are evaluating data from a VA patient population. One study suggested that 
VA populations are not representative of the general North Carolina population102, 103 that 
may seek treatment at a university-sponsored hospital104 nor of the general US population 
as they have lower rates of cancer mortality relative to the whole.105 Furthermore, 
patients at VA hospitals are typically different than people in the generalized population. 
These men and women have health care access, have a relatively standardized level of 
education, have access to preventive care measures, and have encountered the healthcare 
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system.106 VA patients also have, in general, poorer health status and lower 
socioeconomic status than the general population.107 The same cannot be said for every 
American. Thus, while the findings of our DVAMC study suggest a role in race and PC 
risk and aggressiveness, future studies that can deconstruct and evaluate the social 
components of “race” and evaluate them independently along with PC risk and 
aggressiveness are needed. 
 
Our Brazilian-based early PC detection screening program found no association between 
educational status and distance with PC risk and aggressiveness, but did find an increased 
association between risk of non-compliance to biopsy recommendations with distance to 
follow-up care center. While it is known that people in developing countries have less 
access to health care relative to their developed country, distance and education 
contribute to this phenomenon by way of socioeconomic status and income. It can easily 
be argued that those in poverty are undereducated and live in rural areas with limited 
health services access. The gap between the rich and poor is further exacerbated by 
financial barriers – i.e. not having the money to travel to receive health care, or not 
having the luxury of taking the time away from work to go to receive health care – as 
well as informational ones – for example, not understanding the importance of screening, 
medical literature, or knowing what to ask providers when contact is made. It is of most 
importance, to understand how disease affects these rural populations such that when 
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healthcare is needed they have access to it, decreasing the risk of illness caused by 
poverty.48 Specific to PC, studies have linked low socioeconomic status with increased 
risk of dying from PC108, 109 and low educational status with risk of not using early 
detection screening for PC in Latin American populations.90 Knowing this, it seemed 
appropriate to evaluate the association between risk of noncompliance to biopsy 
recommendation, PC risk and PC aggressiveness with distance and education. 
 
Our initial hypothesis that increased distance and lower education would be associated 
with increased risk of non-compliance and increased risk of overall PC was based on the 
premise that distance and education could be used as indicators of socioeconomic status. 
Like education, distance is a complex variable with multiple implications in public health 
research. Increased distance can also imply restricted access. For example, measures of 
distance can encompass geographical distance (km) or physical distance (terrain). Given 
that our hypothesis was based on using geographical distance to care without factoring in 
additional burdens such as finding transportation110, the challenge of lost wages, and 
physical barriers to screening, finding a variable that better encompasses the essence of 
what is actually faced by patients is needed in order to determine whether or not distance 
really matters in the ability to predict disease risk and minimize risk of non-compliance.  
While some literature has shown that the further away a person resides from a provider, 
the less likely they are to come in for routine, follow-up, and screening exams,111 others 
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have shown distance to not be a barrier to receiving care.112 Despite conflicting findings, 
what is left to be determined is whether these measures of distance capture the essence of 
the same construct used to predict adherence and risk. Unfortunately, distance is not just 
a barrier for patients to overcome. Distance challenges are characterized by fewer number 
of care centers in rural areas, fewer physicians with heavier patient loads, and fewer 
incentives for physicians to practice in rural areas due to lower compensation.113 One 
strength of our study is the fact that so many distances (range from 0 – 1500+ km) are 
included in our dataset that we have the capability to examine at what point distance from 
care center no longer matters with respect to compliance, PC risk and PC aggressiveness 
in an environment where the number of care facilities available for initial screening is 
irrelevant.  
 
With respect to education, we hypothesized that lower educational attainment would be 
correlated with increased risk of non-compliance, overall PC, and PC aggressiveness and 
found no associations. The literature has shown that low education is associated with 
higher disease mortality114 in a study of US cancer patients115 but what is unclear is the 
role education plays in adherence or inhibits health related decisions. For the purposes of 
our study, we used education as a marker of socioeconomic status – a compounded 
variable that encompasses a multitude of markers depending on context. More 
specifically, low education could include the level of formal education obtained – which 
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is related to potential future earnings and income, low knowledge about health and 
disease, low health literacy, and lower ability to comprehend health communications with 
providers. Unfortunately, given that there is no defined metric as to what educational 
status means and what it measures, this leaves the door open for potential 
misclassification and interpretation biases in large datasets wherein education may not 
capture what investigators hope it will.  
 
As such, despite the multiple meanings and potential applications of our exposure 
variables, our Brazilian study did highlight several areas where additional study is 
needed. For example, with respect to education, our study had a small sample size for 
patients in higher echelons of educational attainment. Thus, additional studies more 
inclusive of more people with higher levels of educational achievement is needed. 
Furthermore, this cohort was comprised of men with a relatively low cancer detection 
rate, which may have impacted our ability to determine differences in predictability 
between education and distance and overall risk and aggressiveness. While the findings 
of this study are generally negative, additional studies that further explore how education, 
like race, is a multifaceted variable and identify the components thereof, and how to 
better use distance combined with income to terse out the relationship between health 
services access and compliance, are needed.  
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Overall, the independent studies presented in this thesis have shown that health 
disparities do play a role in predicting cancer risk and aggressiveness though the 
mechanism through which they independently act still needs to be explored. Though we 
did not study the relationship between these indices and survivorship, recurrence, or 
factors pertaining to disease onset, the biological mechanism through which race 
mediates tumor growth – be it genetics, epigenetics, or environment – and the ways in 
which education and distance modify the risk of compliance leave the door open for 
future studies. Additionally, these studies set the stage for identifying points at which 
interventions aimed at lowering risk, promoting screening, and increasing healthy 
preventive behaviors can curb the risk and aggressiveness of PC in elderly men at above 
average disease risk.  
 
 
 
 
 
 
 
Appendix A: Figures 
 
Figure 1 – Predictors of PC Cancer Grade on Initial Biopsy (Durham VA Biopsy Study) 
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Figure 2 - Flowchart Describing PC Screening Cohort (Durham VA Biopsy Study)  
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Figure 3 – Crude Association between Black Race and PC/PC Grade on initial biopsy (Durham 
VA Biopsy Study) 
Statistical Analysis: Logistic Regression for Cancer on Biopsy (OR); Multinomial Logistic Regression for 
Cancer Grade on Biopsy (RRR) 
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Figure 4 – Adjusted Association between Black race and PC/PC Grade on initial biopsy (Durham 
VA Biopsy Study) 
Statistical Analysis: Logistic Regression for Cancer on Biopsy (OR); Multinomial Logistic Regression for 
Cancer Grade on Biopsy (RRR)  
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Figure 5 – Predictors of PC Grade on Initial Biopsy (Barretos Cancer Hospital Screening Study 
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Figure 6 – Flowchart Describing PC Screening Cohort (Barretos Cancer Hospital Study)  
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Appendix B: Tables 
Table 1 – Clinical characteristics for men undergoing an initial prostate biopsy at 
the DVAMC, 2001 – 2009 with complete data for all variables (n=887).  
 
Clinical Characteristics at Baseline 
Black 
N = 431 
White 
N = 456 
P* 
 Median (IQR) Median (IQR)  
Year of Biopsy 2005 (2002 – 2006) 2004 (2002 – 2006) 0.290 
Total Number of Cores Taken 11 (8 – 12) 11 (8 – 12) 0.842 
Age at Biopsy (years) 61 (57 – 68) 65 (60 – 70) <0.001 
PSA (ng/mL) 6.6 (4.7 – 12.1) 5.8 (4.4 – 8.4) 0.001 
 No. (%) No. (%) P+ 
BMI (kg/m2) 
< 25 kg/m2 
25 - 29.99 kg/m2 
30 – 34.99 kg/m2 
> 35 kg/m2 
 
110 (25.5) 
160 (37.1) 
114 (26.5) 
47 (10.9) 
 
100 (21.9) 
188 (41.2) 
109 (23.9) 
59 (12.9) 
0.321 
Abnormal DRE 109 (25.3) 141 (30.9) 0.062 
Statistical analyses: * = rank-sum test; + = chi-squared test 
BMI = body mass index; DRE = digital rectal exam; DVAMC = Durham Veteran Affairs Medical Center; 
IQR = Interquartile Range; P = p-value; PSA = prostate specific antigen  
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Table 2 – Biopsy outcomes for men on initial prostate biopsy at the DVAMC, 2001 – 
2009 with complete data for all variables (n=887).  
 
Biopsy Outcomes 
Black 
N = 431 
White 
N = 456 
P* 
 No. (%) No. (%)  
Biopsy outcome   0.001 
No cancer 
Any cancer 
164 (38.1) 
267 (61.9) 
224 (49.1) 
232 (50.9) 
 
    Low-Grade (< 7) 122 (28.3) 123 (27.0)  
    High-Grade (> 7)  145 (33.6) 109 (23.9)  
 Median (IQR) Median (IQR) P+ 
Total number of positive cores among men 
with cancer, IQR 
4 (2 – 6) 3 (1 – 6) 0.084 
Statistical Analyses: * = Rank-sum test for comparison of three outcome categories (no cancer, low-grade, 
high-grade), + = Chi-Squared test 
DVAMC = Durham Veteran Affairs Medical Center; IQR = Interquartile Range; P = p-value for 
comparison of black to white men.  
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Table 3 – Black race as an independent predictor of cancer and cancer grade on 
initial biopsy at the DVAMC, 2001 – 2009 with complete data for all variables 
(n=887).  
Cancer on Biopsy 
Type of Analysis OR 95% CI P 
Crude  1.57 1.20 – 2.05 <0.001 
Adjusted Multivariable 1.50 1.12 – 2.00 0.006 
Cancer Grade on Biopsy 
 RRR 95% CI P 
Crude Multinomial, Relative to No Cancer 
Low-Grade (< 7) 
High-Grade (> 7) 
 
1.36 
1.82 
 
0.98 – 1.87 
1.32 – 2.50 
 
0.064 
<0.001 
Adjusted Multinomial, Relative to No 
Cancer 
Low-Grade (< 7) 
High-Grade (> 7) 
 
 
1.29 
1.84 
 
 
0.92 – 1.80 
1.28 – 2.66 
 
 
0.139 
0.001 
Statistical Analysis: Logistic Regression for Cancer on Biopsy; Multinomial Logistic Regression for 
Cancer Grade on Biopsy 
OR = odds ratio for black race vs. white race; RRR = relative risk ratio for no cancer vs. low-grade vs. 
high-grade; CI = confidence interval; P = p-value 
Models adjusted for age, log-PSA, BMI, DRE and total number of cores taken 
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Table 4 – Descriptive Baseline Characteristics of Men Undergoing Initial PC 
Screening by Brazilian Mobile Medical Units stratified by compliance to biopsy 
recommendation, 2004-2007. 
 
Statistical Analyses: * = rank-sum test; + = chi-squared test  
DRE = digital rectal exam; IQR = interquartile range; P = p-value; PC = prostate cancer; PSA = serum 
prostate specific antigen (ng/mL 
  
 
 
 
Men undergoing 
initial PSA screening 
who were 
recommended for 
biopsy and complied 
with the biopsy 
recommendation 
 
Men undergoing 
initial PSA 
screening who were 
recommended for 
biopsy and did not 
comply with the 
biopsy 
recommendation 
 
P-Values for men 
who complied vs. 
did not comply 
amongst those 
recommended to 
biopsy 
 
Predictors of Compliance 
No. (%)  
P+ N = 1,131 (72.5) N = 430 (27.5) 
Distance from Barretos (km) 
0 – 249.99 km 
250 – 499.99 km 
500 – 999.99 km 
> 1000 km 
 
620 (54.8) 
 289 (25.6) 
 118 (10.4) 
104 (9.2) 
 
75 (17.4) 
70 (16.3) 
84 (19.5) 
201 (46.7) 
<0.001 
Educational Level Attained 
Illiterate 
Incomplete Primary 
Complete Primary 
High School 
College 
 
279 (24.7) 
729 (64.5) 
86 (7.6) 
30 (2.7) 
7 (0.6) 
 
165 (38.4) 
229 (53.3) 
17 (4.0) 
15 (3.5) 
4 (0.9) 
<0.001 
Year of Screening 
2004 
2005 
2006 
2007 
 
230 (20.3) 
355 (31.4) 
333 (29.4) 
213 (18.8) 
 
82 (19.1) 
80 (18.6) 
102 (23.7) 
166 (38.6) 
<0.001 
Positive Family History  
PC 
Any Cancer 
 
56 (5.0) 
122 (10.8) 
 
14 (3.3) 
33 (7.7) 
 
0.15 
0.07 
DRE Suspicious of PC 378 (33.4) 84 (19.5) <0.001 
 Median (IQR) P* 
Age (years) 66 (59 – 72) 68 (62 – 74) <0.001 
Total PSA (ng/mL) 4.17 (2.58 – 7.14) 4.90 (3.45 – 7.72) <0.001 
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Table 5 – Association between Education, Distance & Risk of Non-Compliance 
(n=1561) 
 
Table 5a – Is there an association between distance and non-compliance? 
Model Categories  OR 95% CI P-Value# 
Distance (Relative to 0 – 249.99 km) 
Crude 250 – 499.99 km 2.00 1.40 – 2.85 <0.001 
 500 – 999.99 km 5.88 4.07 – 8.51 
> 1000 km 15.98 11.41 – 22.38 
Adjusted for Age 
Unrestricted 
250 – 499.99 km 1.95 1.37 – 2.79 <0.001 
500 – 999.99 km 5.97 4.12 – 8.66 
> 1000 km 15.86 11.29 – 22.27 
Adjusted for tPSA 250 – 499.99 km 1.89 1.32 – 2.70 <0.001 
500 – 999.99 km 5.53 3.80 – 8.06 
> 1000 km 15.18 10.70 – 21.53 
Adjusted for 
Biopsy Year 
250 – 499.99 km 1.89 1.32 – 2.70 <0.001 
500 – 999.99 km 5.53 3.80 – 8.05 
> 1000 km 14.88 10.57 – 20.95 
Adjusted for 
Abnormal DRE 
250 – 499.99 km 1.90 1.32 – 2.73 <0.001 
500 – 999.99 km 5.52 3.77 – 8.08 
> 1000 km 15.16 10.64 – 21.58 
Adjusted for Family 
History of Any 
Cancer 
250 – 499.99 km 1.88 1.32 – 2.70 <0.001 
500 – 999.99 km 5.53 3.80 – 8.06 
> 1000 km 15.15 10.72 – 21.39 
Adjusted for Family 
History of PC 
250 – 499.99 km 1.89 1.32 – 2.70 <0.001 
500 – 999.99 km 5.53 3.80 – 8.06 
> 1000 km 15.15 10.72 – 21.40 
Statistical Analyses: Logistic Regression; # = likelihood ratio test 
tPSA = logarithmically-transformed; CI = confidence interval; km = kilometers; PC = prostate cancer  
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Table 5 – Association between Education, Distance & Risk of Non-Compliance 
(n=1561) (continued) 
 
Table 5b – Is there an association between educational achievement and non-
compliance?  
Model Categories  OR 95% CI P-Value 
Education (Relative to Illiterate) 
Crude Incomplete Primary 0.53 0.42 – 0.68 <0.001 
Complete Primary 0.33 0.19 – 0.58 
High School + College 0.87 0.48 – 1.56 
Adjusted for Age 
Unrestricted 
Incomplete Primary 0.60 0.47 – 0.77 <0.001 
Complete Primary 0.39 0.22 – 0.68 
High School + College 1.11 0.61 – 2.03 
Adjusted for tPSA  Incomplete Primary 0.59 0.46 – 0.77 <0.001 
Complete Primary 0.41 0.23 – 0.73 
High School + College 1.15 0.62 – 2.13 
Adjusted for Biopsy 
Year 
Incomplete Primary 0.58 0.45 – 0.75 <0.001 
Complete Primary 0.40 0.23 – 0.71 
High School + College 1.13 0.61 – 2.07 
Adjusted for Abnormal 
DRE 
Incomplete Primary 0.59 0.46 – 0.72 <0.001 
Complete Primary 0.43 0.24 – 0.76 
High School + College 1.21 0.65 – 2.25 
Adjusted for Family 
History of Any Cancer 
Incomplete Primary 0.59 0.46 – 0.76 <0.001 
Complete Primary 0.41 0.23 – 0.72 
High School + College 1.15 0.62 – 2.12 
Adjusted for Family 
History of PC 
Incomplete Primary 0.59 0.46 – 0.76 <0.001 
Complete Primary 0.41 0.23 – 0.72 
High School + College 1.15 0.62 – 2.12 
Statistical Analyses: Logistic Regression 
tPSA = logarithmically-transformed; CI = confidence interval; PC = prostate cancer  
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Table 5 – Association between Education, Distance & Risk of Non-Compliance 
(n=1561) (continued) 
 
Table 5c – Refined Multivariable Model of the Association between Distance and 
Education and non-compliance. 
Refined Model with Interaction Term  
Variable Categories OR 95% CI P-Value 
Education (relative to 
Illiterate) 
Incomplete Primary 0.62 0.43 – 0.88 0.003# 
Complete Primary 0.49 0.24 – 1.01 
High School + College 1.24 0.49 – 3.18 
Distance (relative to 
0 – 249.99 km) 
250 – 499.99 km 1.86 1.29 – 2.67 <0.001 
500 – 999.99 km 5.29 3.53 – 7.94 
> 1000 km 14.04 8.56 – 23.03 
Age  1.03 1.01 – 1.04 <0.001 
Biopsy Year  1.21 1.07 – 1.36 0.003 
Distance x Education    0.84 
Statistical Analyses: Logistic Regression, # = Likelihood Ratio Test 
Multivariable Analysis adjusted for Age and Biopsy Year; tPSA = logarithmically-transformed 
CI = confidence interval; km = kilometers; PC = prostate cancer 
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Table 5 – Association between Education, Distance & Risk of Non-Compliance 
(n=1561) (continued) 
 
Table 5d – Multivariable Analyses of Distance and Educational Achievement Non-
Compliance 
Variable Categories OR 95% CI P-Value# 
Education 
(relative to 
Illiterate) 
Incomplete Primary 0.63 0.47 – 0.84 0.002 
Complete Primary 0.51 0.27 – 0.94 
High School + College 1.32 0.65 – 2.67 
Distance (relative 
to 0 – 249.99 km) 
250 – 499.99 km 1.87 1.30 – 2.68 <0.001 
500 – 999.99 km 5.37 3.68 – 7.84 
> 1000 km 14.60 10.34 – 20.60 
Statistical Analyses: Logistic Regression, # = Likelihood Ratio Test 
Multivariable Analysis adjusted for Age and Biopsy Year; tPSA = logarithmically-transformed 
CI = confidence interval; km = kilometers; PC = prostate cancer 
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Table 6 – Descriptive Baseline Clinical Characteristics of Men who Underwent 
Initial Biopsy stratified by Educational Status at Barretos Cancer Hospital, 
Barretos, SP, Brazil (n=858) 
 
Statistical Tests: * = analysis of variance test (ANOVA); + = chi-squared test 
 Educational Status  
Illiterate Incomplete 
Primary 
School 
Complete 
Primary 
School 
High School 
& College 
 
Baseline Clinical 
Characteristics 
N = 223 
(26.0) 
N = 551 
(64.2) 
N = 60  
(7.0)  
N = 24  
(2.8) 
P* 
Median (IQR) 
Age (years) 69 (64 – 76) 65 (59 – 71) 64 (56 – 72) 58 (53 – 65) <0.001 
Total PSA (ng/mL) 6.04  
(3.65 – 11.87) 
4.47  
(2.94 – 7.43) 
4.73  
(2.57 – 9.08) 
4.16  
(2.75 – 7.68) 
0.001 
 No (%) P+ 
Distance from Barretos 
(km) 
0 – 249.99 km 
250 – 499.99 km 
500 – 999.99 km 
> 1000 km 
 
103 (46.2) 
67 (30.0) 
28 (12.6) 
25 (11.2) 
 
301 (54.6) 
139 (25.2) 
55 (10.0) 
56 (10.2) 
 
33 (55.0) 
18 (33.0) 
4 (6.7) 
5 (8.3) 
 
16 (66.7) 
3 (12.5) 
3 (12.5) 
2 (8.3) 
0.43 
Year of Screening 
2004 
2005 
2006 
2007 
 
52 (23.3) 
64 (28.7) 
62 (27.8) 
45 (20.2) 
 
111 (20.2) 
161 (29.2) 
174 (31.6) 
105 (19.1) 
 
12 (20.0) 
29 (48.3) 
14 (23.3) 
5 (8.3) 
 
5 (20.8) 
7 (29.2) 
10 (41.7) 
2 (8.3) 
0.08 
DRE Suspicious of PC 47 (21.1) 139 (25.2) 13 (21.7) 8 (33.3) 0.42 
Positive Family History 
Any Cancer 
PC 
 
14 (6.3) 
4 (1.8) 
 
60 (10.9) 
22 (4.0) 
 
6 (10.0) 
5 (8.3) 
 
5 (20.8) 
2 (8.3) 
 
0.07 
0.07 
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Table 7 – Prostate Biopsy Outcomes among men undergoing initial biopsy after 
recommendation by Brasilian Mobile Medical Units following an abnormal screen, 
2004-2007. 
 
Biopsy Outcomes 
 
No. (%) 
Cancer Status on First Biopsy 
Positive 
Negative 
 
320 (37.7) 
530 (62.4) 
Cancer Details among men with Cancer and Complete Data, N = 318 
Gleason Score 
2 – 6 
7 
8 – 10 
 
207 (65.1) 
85 (26.7) 
26 (8.2) 
Clinical Stage 
Stage I 
Stage II 
Stage III 
Stage IV 
 
237 (74.5) 
42 (13.2) 
16 (5.0) 
23 (7.2) 
Transrectal Ultrasound Findings 
Normal 
Hypoechoic Nodules 
Hyperechoic Nodules 
 
106 (33.3) 
211 (66.4) 
1 (0.3) 
 Median (IQR) 
Total Number of Positive Cores 3 (2 – 5) 
Total Number of Cores Taken 12 (10 – 14) 
Prostate Volume (cc) 33 (25 – 46) 
tPSA (ng/mL) 7 (4 – 16) 
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Table 8 – The Association between Education and Distance and Cancer on Initial 
Biopsy of all men who had a biopsy (n=858) 
 
Table 8a – Is there an association between distance and having cancer on initial biopsy? 
Model Categories  OR 95% CI P-Value# 
Distance (Relative to 0 – 249.99 km) 
Crude 250 – 499.99 km 1.05 0.76 – 1.46 0.37 
500 – 999.99 km 0.87 0.54 – 1.40 
> 1000 km 1.45 0.91 – 2.30 
Adjusted for Age 
Unrestricted 
250 – 499.99 km 1.05 0.75 – 1.46 0.34 
500 – 999.99 km 0.89 0.55 – 1.45 
> 1000 km 1.50 0.94 – 2.38 
Adjusted for Total 
Number of Cores Taken 
250 – 499.99 km 1.01 0.72 – 1.41 0.37 
500 – 999.99 km 0.84 0.52 – 1.36 
> 1000 km 1.43 0.90 – 2.28 
Adjusted for Biopsy 
Year 
250 – 499.99 km 1.01 0.72 – 1.41 0.37 
500 – 999.99 km 0.81 0.50 – 1.32 
> 1000 km 1.40 0.87 – 2.24 
Adjusted for Family 
History of Any Cancer 
250 – 499.99 km 0.99 0.71 – 1.39 0.32 
500 – 999.99 km 0.81 0.50 – 1.32 
> 1000 km 1.43 0.89 – 2.30 
Adjusted for Family 
History of PC 
250 – 499.99 km 0.99 0.71 – 1.39 0.33 
500 – 999.99 km 0.81 0.50 – 1.33 
> 1000 km 1.43 0.89 – 2.30 
Statistical Analyses: Logistic Regression, # = Likelihood Ratio Test 
CI = confidence interval; km = kilometers; PC = prostate cancer 
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Table 8 – The Association between Education and Distance and Cancer on Initial 
Biopsy of all men who had a biopsy (n=858) (continued) 
 
Table 8b – Is there an association between educational achievement and having cancer 
on initial biopsy?  
Model Categories  OR 95% CI P-Value# 
Education (Relative to Illiterate) 
Crude Incomplete Primary 1.03 0.75 – 1.42 0.57 
Complete Primary 0.89 0.49 – 1.62 
High School + College 0.55 0.21 – 1.44 
Adjusted for Age 
Unrestricted 
Incomplete Primary 1.17 0.84 – 1.63 0.66 
Complete Primary 1.06 0.58 – 1.96 
High School + College 0.78 0.29 – 2.07 
Adjusted for Total 
Number of Cores Taken 
Incomplete Primary 1.18 0.85 – 1.65 0.63 
Complete Primary 1.09 0.59 – 2.02 
High School + College 0.76 0.28 – 2.04 
Adjusted for Biopsy Year Incomplete Primary 1.17 0.84 – 1.63 0.69 
Complete Primary 1.13 0.61 – 2.09 
High School + College 0.78 0.29 – 2.10 
Adjusted for Family 
History of Any Cancer 
Incomplete Primary 1.16 0.83 – 1.62 0.68 
Complete Primary 1.12 0.61 – 2.07 
High School + College 0.75 0.28 – 2.01 
Adjusted for Family 
History of PC 
Incomplete Primary 1.16 0.83 – 1.62 0.68 
Complete Primary 1.12 0.60 – 2.06 
High School + College 0.75 0.28 – 2.02 
Statistical Analyses: Logistic Regression; # =Likelihood Ratio Test 
CI = confidence interval; PC = prostate cancer 
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Table 8 – The Association between Education and Distance and Cancer on Initial 
Biopsy of all men who had a biopsy (n=858) (continued) 
 
Table 8c – Refined Multivariable Model of the Association between Distance and 
Education and having cancer on initial biopsy. 
Refined Model with Interaction Term  
Variable Categories OR 95% CI P-Value 
Education (relative to 
Illiterate) 
Incomplete Primary 1.24 0.85 – 1.81 0.62# 
Complete Primary 1.17 0.59 – 2.32 
High School + College 0.92 0.30 – 2.86 
Distance (relative to 0 – 
249.99 km) 
250 – 499.99 km 1.08 0.76 – 1.52 0.39# 
500 – 999.99 km 0.95 0.56 – 1.60 
> 1000 km 1.72 0.85 – 3.49 
Age  1.04 1.02 – 1.05 <0.001 
Distance x Education    0.60 
Statistical Analyses: Logistic Regression, # = Likelihood Ratio Test 
Multivariable Analysis adjusted for Age 
CI = confidence interval; km = kilometers; PC = prostate cancer 
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Table 8 – The Association between Education and Distance and Cancer on Initial 
Biopsy of all men who had a biopsy (n=858) (continued) 
 
Table 8d – Multivariable Analyses of Distance and Educational Achievement and having 
cancer on initial biopsy? 
Variable Categories OR 95% CI P-Value# 
Education (relative to 
Illiterate) 
Incomplete Primary 1.18 0.85 – 1.65 0.39 
Complete Primary 1.07 0.58 – 1.97 
High School + College 0.79 0.29 – 2.13 
Distance (relative to 0 – 
249.99 km) 
250 – 499.99 km 1.06 0.76 – 1.47 0.34 
500 – 999.99 km 0.90 0.55 – 1.46 
> 1000 km 1.49 0.94 – 2.38 
Statistical Analyses: Logistic Regression, # = Likelihood Ratio Test 
Multivariable Analysis adjusted for Age 
CI = confidence interval; km = kilometers; PC = prostate cancer 
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Table 9 – The Association between Education and Distance and Biopsy Cancer 
Grade Relative to no cancer (n=858) 
 
Table 9a – Is there an association between distance and cancer grade on initial biopsy? 
Model Categories  RRR 95% CI P-Value# 
Cancer Outcome: Low-Grade Cancer, Gleason < 7 
Distance (Relative to 0 – 249.99 km) 
Crude 250 – 499.99 km 0.97 0.69 – 1.36 0.27 
500 – 999.99 km 0.86 0.53 – 1.41 
> 1000 km 1.39 0.86 – 2.23 
Adjusted for Age 250 – 499.99 km 0.97 0.69 – 1.37 0.26 
500 – 999.99 km 0.88 0.54 – 1.44 
> 1000 km 1.42 0.88 – 2.29 
Adjusted for 
Total Number of 
Cores Taken 
250 – 499.99 km 0.93 0.66 – 1.32 0.30 
500 – 999.99 km 0.83 0.51 – 1.36 
> 1000 km 1.37 0.85 – 2.21 
Adjusted for 
Biopsy Year 
250 – 499.99 km 0.93 0.66 – 1.32 0.32 
500 – 999.99 km 0.81 0.49 – 1.33 
> 1000 km 1.34 0.83 – 2.17 
Adjusted for 
Family History of 
Any Cancer 
250 – 499.99 km 0.92 0.65 – 1.30 0.29 
500 – 999.99 km 0.81 0.49 – 1.33 
> 1000 km 1.38 0.85 – 2.23 
Adjusted for 
Family History of 
PC 
250 – 499.99 km 0.92 0.65 – 1.30 0.29 
500 – 999.99 km 0.81 0.49 – 1.33 
> 1000 km 1.38 0.85 – 2.23 
Cancer Outcome: High-Grade Cancer, Gleason > 7 
Crude 250 – 499.99 km 2.44 1.03 – 5.79 0.27 
500 – 999.99 km 0.96 0.21 – 4.51 
> 1000 km 2.41 0.73 – 7.99 
Adjusted for Age 250 – 499.99 km 2.38 0.99 – 5.74 0.26 
500 – 999.99 km 1.10 0.23 – 5.26 
> 1000 km 2.93 0.86 – 9.98 
Adjusted for 
Total Number of 
Cores Taken 
250 – 499.99 km 2.23 0.92 – 5.40 0.30 
500 – 999.99 km 0.98 0.21 – 4.72 
> 1000 km 2.69 0.79 – 9.20 
Adjusted for 
Biopsy Year 
250 – 499.99 km 2.23 0.92 – 5.41 0.32 
500 – 999.99 km 0.85 0.17 – 4.16 
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> 1000 km 2.35 0.68 – 8.16 
Adjusted for 
Family History of 
Any Cancer 
250 – 499.99 km 2.20 0.92 – 5.34 0.29 
500 – 999.99 km 0.85 0.17 – 4.17 
> 1000 km 2.44 0.70 – 8.55 
Adjusted for 
Family History of 
PC 
250 – 499.99 km 2.19 0.90 – 5.34 0.29 
500 – 999.99 km 0.86 0.18 – 4.20 
> 1000 km 2.44 0.70 – 8.54 
Statistical Analyses: Multinomial Logistic Regression; # = Likelihood Ratio Test 
Educational Attainment defined as: Low-Education (Illiterate, Incomplete Primary) vs. High-Education 
(Complete Primary, High School, College) 
CI = confidence interval; Km = kilometers; PC = prostate cancer; RRR = relative risk ratio 
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Table 9 – The Association between Education and Distance and Biopsy Cancer 
Grade Relative to no cancer (n=858) (continued) 
 
Table 9b – Is there an association between educational achievement and cancer grade on 
initial biopsy?  
Model RRR 95% CI P-Value 
Cancer Outcome: Low-Grade Cancer, Gleason < 7 
Educational Attainment (Relative to Low-Education) 
Crude 0.75 0.45 – 1.23 0.25 
Adjusted for Age 0.83 0.50 – 1.37 0.46 
Adjusted for Total Number of 
Cores Taken 
0.83 0.50 – 1.39 0.48 
Adjusted for Biopsy Year 0.86 0.52 – 1.43 0.57 
Adjusted for Family History of Any 
Cancer 
0.85 0.51 – 1.42 0.54 
Adjusted for Family History of PC 0.85 0.51 – 1.42 0.53 
Cancer Outcome: High-Grade Cancer, Gleason > 7 
Crude 1.01 0.30 – 3.45 0.99 
Adjusted for Age 1.38 0.39 – 4.88 0.62 
Adjusted for Total Number of 
Cores Taken 
1.45 0.41 – 5.15 0.57 
Adjusted for Biopsy Year 1.69 0.47 – 6.11 0.43 
Adjusted for Family History of Any 
Cancer 
1.68 0.46 – 6.09 0.43 
Adjusted for Family History of PC 1.68 0.46 – 6.07 0.43 
Statistical Analyses: Multinomial Logistic Regression 
Educational Attainment defined as: Low-Education (Illiterate, Incomplete Primary) vs. High-Education 
(Complete Primary, High School, College) 
CI = confidence interval; PC = prostate cancer; RRR = relative risk ratio 
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Table 9 – The Association between Education and Distance and Biopsy Cancer 
Grade Relative to no cancer (n=858) (continued) 
 
Table 9c – Refined Multivariable Model of the Association between Distance and 
Education and cancer grade on initial biopsy. 
Variable Categories RRR 95% CI P-Value 
Cancer Outcome: Low-Grade Cancer, Gleason < 7 
Education (relative to Low-
Education) 
 0.87 0.50 – 1.51 0.61 
Distance (relative to 0 – 
249.99 km) 
250 – 499.99 km 0.93 0.65 – 1.32 0.36# 
500 – 999.99 km 0.80 0.48 – 1.36 
> 1000 km 1.34 0.69 – 2.62 
Age  1.03 1.01 – 1.04 0.002 
Biopsy Year  1.16 0.98 – 1.38 0.08 
Total Number of Cores 
Taken 
 1.03 0.97 – 1.09 0.34 
Distance x Education    0.97 
Cancer Outcome: High-Grade Cancer, Gleason > 7 
Education (relative to Low-
Education) 
 1.79 0.44 – 7.32 0.42  
Distance (relative to 0 – 
249.99 km) 
250 – 499.99 km 2.25 0.92 – 5.50 0.36# 
500 – 999.99 km 0.89 0.18 – 4.51 
> 1000 km 2.63 0.57 – 12.18 
Age  1.12 1.07 – 1.17 <0.001 
Biopsy Year  1.71 1.08 – 2.69 0.02 
Total Number of Cores 
Taken 
 1.03 0.88 – 1.20 0.71 
Distance x Education    0.80 
Statistical Analyses: Multinomial Logistic Regression, # = Likelihood Ratio Test 
Educational Attainment defined as: Low-Education (Illiterate, Incomplete Primary) vs. High-Education 
(Complete Primary, High School, College) 
Multivariable analysis adjusted for Age, Biopsy Year and Total Number of Cores Taken 
CI = confidence interval; Km = kilometers; PC = prostate cancer; RRR = relative risk ratio 
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Table 9 – The Association between Education and Distance and Biopsy Cancer 
Grade Relative to no cancer (n=858) (continued) 
 
Table 9d – Multivariable Analyses of Distance and Educational Achievement and cancer 
grade on initial biopsy? 
Variable Categories RRR 95% CI P-
Value 
Cancer Outcome: Low-Grade Cancer, Gleason < 7 
Education (relative 
to Low Education) 
 0.86 0.52 – 1.44 0.57 
Distance (relative to 
0 – 249.99 km) 
250 – 499.99 km 0.93 0.66 – 1.32 0.32# 
500 – 999.99 km 0.80 0.49 – 1.32 
> 1000 km 1.33 0.82 – 2.15 
Cancer Outcome: High-Grade Cancer, Gleason > 7 
Education (relative 
to Low-Education) 
 1.65 0.46 – 6.00 0.44 
Distance (relative to 
0 – 249.99 km) 
250 – 499.99 km 2.22 0.91 – 5.39 0.32# 
500 – 999.99 km 0.86 0.18 – 4.18 
> 1000 km 2.34 0.67 – 8.13 
Statistical Analyses: Multinomial Logistic Regression, # = Likelihood Ratio Test 
Educational Attainment defined as: Low-Education (Illiterate, Incomplete Primary) vs. High-Education 
(Complete Primary, High School, College) 
Multivariable analysis adjusted for Age, Biopsy Year and Total Number of Cores Taken 
CI = confidence interval; Km = kilometers; PC = prostate cancer; RRR = relative risk ratio 
  	  
	  	   86  
References 1.	   Thun,	  M.	  J.,	  DeLancey,	  J.	  O.,	  Center,	  M.	  M.	  et	  al.:	  The	  global	  burden	  of	  cancer:	  priorities	  for	  prevention.	  Carcinogenesis,	  31:	  100,	  2010	  2.	   Delongchamps,	  N.	  B.,	  Singh,	  A.,	  Haas,	  G.	  P.:	  The	  role	  of	  prevalence	  in	  the	  diagnosis	  of	  prostate	  cancer.	  Cancer	  Control,	  13:	  158,	  2006	  3.	   Potosky,	  A.	  L.,	  Feuer,	  E.	  J.,	  Levin,	  D.	  L.:	  Impact	  of	  screening	  on	  incidence	  and	  mortality	  of	  prostate	  cancer	  in	  the	  United	  States.	  Epidemiol	  Rev,	  23:	  181,	  2001	  4.	   Bray,	  F.,	  Moller,	  B.:	  Predicting	  the	  future	  burden	  of	  cancer.	  Nat	  Rev	  Cancer,	  6:	  63,	  2006	  5.	   Masko,	  E.	  M.,	  Allott,	  E.	  H.,	  Freedland,	  S.	  J.:	  The	  relationship	  between	  nutrition	  and	  prostate	  cancer:	  is	  more	  always	  better?	  Eur	  Urol,	  63:	  810,	  2013	  6.	   Ezzati,	  M.,	  Henley,	  S.	  J.,	  Lopez,	  A.	  D.	  et	  al.:	  Role	  of	  smoking	  in	  global	  and	  regional	  cancer	  epidemiology:	  current	  patterns	  and	  data	  needs.	  Int	  J	  Cancer,	  
116:	  963,	  2005	  7.	   Jha,	  P.:	  Avoidable	  global	  cancer	  deaths	  and	  total	  deaths	  from	  smoking.	  Nat	  Rev	  Cancer,	  9:	  655,	  2009	  8.	   Calle,	  E.	  E.,	  Rodriguez,	  C.,	  Walker-­‐Thurmond,	  K.	  et	  al.:	  Overweight,	  obesity,	  and	  mortality	  from	  cancer	  in	  a	  prospectively	  studied	  cohort	  of	  U.S.	  adults.	  N	  Engl	  J	  Med,	  348:	  1625,	  2003	  9.	   Sandhu,	  G.	  S.,	  Andriole,	  G.	  L.:	  Overdiagnosis	  of	  prostate	  cancer.	  J	  Natl	  Cancer	  Inst	  Monogr,	  2012:	  146,	  2012	  10.	   Etzioni,	  R.,	  Penson,	  D.	  F.,	  Legler,	  J.	  M.	  et	  al.:	  Overdiagnosis	  due	  to	  prostate-­‐specific	  antigen	  screening:	  lessons	  from	  U.S.	  prostate	  cancer	  incidence	  trends.	  J	  Natl	  Cancer	  Inst,	  94:	  981,	  2002	  11.	   Kanavos,	  P.:	  The	  rising	  burden	  of	  cancer	  in	  the	  developing	  world.	  Ann	  Oncol,	  
17	  Suppl	  8:	  viii15,	  2006	  12.	   Siegel,	  R.,	  Naishadham,	  D.,	  Jemal,	  A.:	  Cancer	  statistics,	  2013.	  CA	  Cancer	  J	  Clin,	  
63:	  11,	  2013	  
  	  
	  	   87  
13.	   Potosky,	  A.	  L.,	  Miller,	  B.	  A.,	  Albertsen,	  P.	  C.	  et	  al.:	  The	  role	  of	  increasing	  detection	  in	  the	  rising	  incidence	  of	  prostate	  cancer.	  JAMA,	  273:	  548,	  1995	  14.	   Fonseca,	  L.	  A.,	  Eluf-­‐Neto,	  J.,	  Wunsch	  Filho,	  V.:	  [Cancer	  mortality	  trends	  in	  Brazilian	  state	  capitals,	  1980-­‐2004].	  Rev	  Assoc	  Med	  Bras,	  56:	  309,	  2010	  15.	   Bock,	  C.	  H.,	  Schwartz,	  A.	  G.,	  Ruterbusch,	  J.	  J.	  et	  al.:	  Results	  from	  a	  prostate	  cancer	  admixture	  mapping	  study	  in	  African-­‐American	  men.	  Hum	  Genet,	  126:	  637,	  2009	  16.	   Ricks-­‐Santi,	  L.	  J.,	  Apprey,	  V.,	  Mason,	  T.	  et	  al.:	  Identification	  of	  genetic	  risk	  associated	  with	  prostate	  cancer	  using	  ancestry	  informative	  markers.	  Prostate	  Cancer	  Prostatic	  Dis,	  15:	  359,	  2012	  17.	   Ward,	  E.,	  Jemal,	  A.,	  Cokkinides,	  V.	  et	  al.:	  Cancer	  disparities	  by	  race/ethnicity	  and	  socioeconomic	  status.	  CA	  Cancer	  J	  Clin,	  54:	  78,	  2004	  18.	   Vashi,	  A.	  R.,	  Oesterling,	  J.	  E.:	  Percent	  free	  prostate-­‐specific	  antigen:	  entering	  a	  new	  era	  in	  the	  detection	  of	  prostate	  cancer.	  Mayo	  Clin	  Proc,	  72:	  337,	  1997	  19.	   Walz,	  J.,	  Haese,	  A.,	  Scattoni,	  V.	  et	  al.:	  Percent	  free	  prostate-­‐specific	  antigen	  (PSA)	  is	  an	  accurate	  predictor	  of	  prostate	  cancer	  risk	  in	  men	  with	  serum	  PSA	  2.5	  ng/mL	  and	  lower.	  Cancer,	  113:	  2695,	  2008	  20.	   Faria,	  E.	  F.,	  Carvalhal,	  G.	  F.,	  dos	  Reis,	  R.	  B.	  et	  al.:	  Use	  of	  low	  free	  to	  total	  PSA	  ratio	  in	  prostate	  cancer	  screening:	  detection	  rates,	  clinical	  and	  pathological	  findings	  in	  Brazilian	  men	  with	  serum	  PSA	  levels	  <4.0	  ng/mL.	  BJU	  Int,	  110:	  E653,	  2012	  21.	   Ahmed,	  M.:	  Prostate	  cancer	  diagnosis	  in	  a	  resource-­‐poor	  setting:	  the	  changing	  role	  of	  digital	  rectal	  examination.	  Trop	  Doct,	  41:	  141,	  2011	  22.	   Potts,	  J.	  M.,	  Lutz,	  M.,	  Walker,	  E.	  et	  al.:	  Trends	  in	  PSA,	  age	  and	  prostate	  cancer	  detection	  among	  black	  and	  white	  men	  from	  1990-­‐2006	  at	  a	  tertiary	  care	  center.	  Cancer,	  116:	  3910,	  2010	  23.	   Delahunt,	  B.,	  Miller,	  R.	  J.,	  Srigley,	  J.	  R.	  et	  al.:	  Gleason	  grading:	  past,	  present	  and	  future.	  Histopathology,	  60:	  75,	  2012	  24.	   Gann,	  P.	  H.:	  Risk	  factors	  for	  prostate	  cancer.	  Rev	  Urol,	  4	  Suppl	  5:	  S3,	  2002	  
  	  
	  	   88  
25.	   Crawford,	  E.	  D.,	  Abrahamsson,	  P.	  A.:	  PSA-­‐based	  screening	  for	  prostate	  cancer:	  how	  does	  it	  compare	  with	  other	  cancer	  screening	  tests?	  Eur	  Urol,	  54:	  262,	  2008	  26.	   Freedland,	  S.	  J.,	  Isaacs,	  W.	  B.:	  Explaining	  racial	  differences	  in	  prostate	  cancer	  in	  the	  United	  States:	  sociology	  or	  biology?	  Prostate,	  62:	  243,	  2005	  27.	   Porter,	  C.	  R.,	  Kim,	  J.:	  Low	  AUA	  symptom	  score	  independently	  predicts	  positive	  prostate	  needle	  biopsy:	  results	  from	  a	  racially	  diverse	  series	  of	  411	  patients.	  Urology,	  63:	  90,	  2004	  28.	   Heath,	  E.	  I.,	  Kattan,	  M.	  W.,	  Powell,	  I.	  J.	  et	  al.:	  The	  effect	  of	  race/ethnicity	  on	  the	  accuracy	  of	  the	  2001	  Partin	  Tables	  for	  predicting	  pathologic	  stage	  of	  localized	  prostate	  cancer.	  Urology,	  71:	  151,	  2008	  29.	   Partin,	  A.	  W.,	  Mangold,	  L.	  A.,	  Lamm,	  D.	  M.	  et	  al.:	  Contemporary	  update	  of	  prostate	  cancer	  staging	  nomograms	  (Partin	  Tables)	  for	  the	  new	  millennium.	  Urology,	  58:	  843,	  2001	  30.	   Kilbourne,	  A.	  M.,	  Switzer,	  G.,	  Hyman,	  K.	  et	  al.:	  Advancing	  health	  disparities	  research	  within	  the	  health	  care	  system:	  a	  conceptual	  framework.	  Am	  J	  Public	  Health,	  96:	  2113,	  2006	  31.	   Thomas,	  S.	  B.,	  Quinn,	  S.	  C.,	  Butler,	  J.	  et	  al.:	  Toward	  a	  fourth	  generation	  of	  disparities	  research	  to	  achieve	  health	  equity.	  Annu	  Rev	  Public	  Health,	  32:	  399,	  2011	  32.	   Chu,	  D.	  I.,	  Freedland,	  S.	  J.:	  Prostate	  cancer.	  Socioeconomic	  status	  and	  disparities	  in	  treatment	  patterns.	  Nat	  Rev	  Urol,	  7:	  480,	  2010	  33.	   DeLancey,	  J.	  O.,	  Thun,	  M.	  J.,	  Jemal,	  A.	  et	  al.:	  Recent	  trends	  in	  Black-­‐White	  disparities	  in	  cancer	  mortality.	  Cancer	  Epidemiol	  Biomarkers	  Prev,	  17:	  2908,	  2008	  34.	   Smaje,	  C.:	  Not	  just	  a	  Social	  Construct:	  Theorising	  Race	  and	  Ethnicity.	  Sociology,	  31:	  307,	  1997	  35.	   Machery,	  E.	  a.	  F.,	  L:	  Social	  Construction	  and	  the	  Concept	  of	  Race.	  Philosophy	  of	  Science,	  72:	  1208,	  2005	  36.	   Marger,	  M.:	  Race	  and	  ethnic	  relations:	  American	  and	  global	  perspectives,	  2	  ed.	  Belmont,	  California:	  Wadsworth	  Publishing	  Company	  1991	  
  	  
	  	   89  
37.	   Grunkemeier,	  M.	  N.,	  Vollmer,	  R.	  T.:	  Predicting	  prostate	  biopsy	  results:	  The	  importance	  of	  PSA,	  age,	  and	  race.	  Am	  J	  Clin	  Pathol,	  126:	  110,	  2006	  38.	   Yanke,	  B.	  V.,	  Carver,	  B.	  S.,	  Bianco,	  F.	  J.,	  Jr.	  et	  al.:	  African-­‐American	  race	  is	  a	  predictor	  of	  prostate	  cancer	  detection:	  incorporation	  into	  a	  pre-­‐biopsy	  nomogram.	  BJU	  Int,	  98:	  783,	  2006	  39.	   Cooper,	  R.	  S.:	  Race	  in	  biological	  and	  biomedical	  research.	  Cold	  Spring	  Harb	  Perspect	  Med,	  3,	  2013	  40.	   Winkleby,	  M.	  A.,	  Jatulis,	  D.	  E.,	  Frank,	  E.	  et	  al.:	  Socioeconomic	  status	  and	  health:	  how	  education,	  income,	  and	  occupation	  contribute	  to	  risk	  factors	  for	  cardiovascular	  disease.	  Am	  J	  Public	  Health,	  82:	  816,	  1992	  41.	   Becker,	  G.	  S.:	  Human	  Capital:	  A	  Theoretical	  and	  Empirical	  Analysis	  with	  Special	  Reference	  to	  Education,	  3	  ed.	  Chicago,	  Illinois:	  University	  of	  Chicago	  Press	  p.	  412,	  2009	  42.	   Nutbeam,	  D.:	  Health	  literacy	  as	  a	  public	  health	  goal:	  a	  challenge	  for	  contemporary	  health	  education	  and	  communication	  strategies	  into	  the	  21st	  century.	  Health	  Promot.	  Int.	  ,	  15:	  259,	  2000	  43.	   Braveman,	  P.	  A.,	  Cubbin,	  C.,	  Egerter,	  S.	  et	  al.:	  Socioeconomic	  status	  in	  health	  research:	  one	  size	  does	  not	  fit	  all.	  JAMA,	  294:	  2879,	  2005	  44.	   Anderson,	  N.	  B.,	  Armstead,	  C.	  A.:	  Toward	  understanding	  the	  association	  of	  socioeconomic	  status	  and	  health:	  a	  new	  challenge	  for	  the	  biopsychosocial	  approach.	  Psychosom	  Med,	  57:	  213,	  1995	  45.	   Rogers,	  A.,	  Flowers,	  J.,	  Pencheon,	  D.:	  Improving	  access	  needs	  a	  whole	  systems	  approach.	  And	  will	  be	  important	  in	  averting	  crises	  in	  the	  millennium	  winter.	  BMJ,	  319:	  866,	  1999	  46.	   Gulliford,	  M.,	  Figueroa-­‐Munoz,	  J.,	  Morgan,	  M.	  et	  al.:	  What	  does	  'access	  to	  health	  care'	  mean?	  J	  Health	  Serv	  Res	  Policy,	  7:	  186,	  2002	  47.	   Greenberg,	  C.	  C.,	  Weeks,	  J.	  C.,	  Stain,	  S.	  C.:	  Disparities	  in	  oncologic	  surgery.	  World	  J	  Surg,	  32:	  522,	  2008	  48.	   Peters,	  D.	  H.,	  Garg,	  A.,	  Bloom,	  G.	  et	  al.:	  Poverty	  and	  access	  to	  health	  care	  in	  developing	  countries.	  Ann	  N	  Y	  Acad	  Sci,	  1136:	  161,	  2008	  
  	  
	  	   90  
49.	   Mulley,	  A.	  G.,	  Jr.:	  Developing	  skills	  for	  evidence-­‐based	  surgery:	  ensuring	  that	  patients	  make	  informed	  decisions.	  Surg	  Clin	  North	  Am,	  86:	  181,	  2006	  50.	   Sepucha,	  K.	  R.,	  Fowler,	  F.	  J.,	  Jr.,	  Mulley,	  A.	  G.,	  Jr.:	  Policy	  support	  for	  patient-­‐centered	  care:	  the	  need	  for	  measurable	  improvements	  in	  decision	  quality.	  Health	  Aff	  (Millwood),	  Suppl	  Variation:	  VAR54,	  2004	  51.	   Moreira,	  D.	  M.,	  Anderson,	  T.,	  Gerber,	  L.	  et	  al.:	  The	  association	  of	  diabetes	  mellitus	  and	  high-­‐grade	  prostate	  cancer	  in	  a	  multiethnic	  biopsy	  series.	  Cancer	  Causes	  Control,	  22:	  977,	  2011	  52.	   Flegal,	  K.	  M.,	  Carroll,	  M.	  D.,	  Kit,	  B.	  K.	  et	  al.:	  Prevalence	  of	  obesity	  and	  trends	  in	  the	  distribution	  of	  body	  mass	  index	  among	  US	  adults,	  1999-­‐2010.	  JAMA,	  307:	  491,	  2012	  53.	   Cossrow,	  N.,	  Falkner,	  B.:	  Race/ethnic	  issues	  in	  obesity	  and	  obesity-­‐related	  comorbidities.	  J	  Clin	  Endocrinol	  Metab,	  89:	  2590,	  2004	  54.	   Freedland,	  S.	  J.,	  Wen,	  J.,	  Wuerstle,	  M.	  et	  al.:	  Obesity	  is	  a	  significant	  risk	  factor	  for	  prostate	  cancer	  at	  the	  time	  of	  biopsy.	  Urology,	  72:	  1102,	  2008	  55.	   Banez,	  L.	  L.,	  Hamilton,	  R.	  J.,	  Partin,	  A.	  W.	  et	  al.:	  Obesity-­‐related	  plasma	  hemodilution	  and	  PSA	  concentration	  among	  men	  with	  prostate	  cancer.	  JAMA,	  
298:	  2275,	  2007	  56.	   Newton,	  M.	  R.,	  Phillips,	  S.,	  Chang,	  S.	  S.	  et	  al.:	  Smaller	  prostate	  size	  predicts	  high	  grade	  prostate	  cancer	  at	  final	  pathology.	  J	  Urol,	  184:	  930,	  2010	  57.	   Freedland,	  S.	  J.,	  Isaacs,	  W.	  B.,	  Platz,	  E.	  A.	  et	  al.:	  Prostate	  size	  and	  risk	  of	  high-­‐grade,	  advanced	  prostate	  cancer	  and	  biochemical	  progression	  after	  radical	  prostatectomy:	  a	  search	  database	  study.	  J	  Clin	  Oncol,	  23:	  7546,	  2005	  58.	   Bozeman,	  C.	  B.,	  Carver,	  B.	  S.,	  Caldito,	  G.	  et	  al.:	  Prostate	  cancer	  in	  patients	  with	  an	  abnormal	  digital	  rectal	  examination	  and	  serum	  prostate-­‐specific	  antigen	  less	  than	  4.0	  ng/mL.	  Urology,	  66:	  803,	  2005	  59.	   Nativ,	  O.,	  Sabo,	  E.,	  Wald,	  M.	  et	  al.:	  Relationship	  between	  prostate	  size	  and	  percent	  free	  prostate-­‐specific	  antigen	  in	  patients	  with	  operable	  prostate	  cancer.	  Isr	  Med	  Assoc	  J,	  2:	  889,	  2000	  
  	  
	  	   91  
60.	   Kim,	  Y.	  M.,	  Park,	  S.,	  Kim,	  J.	  et	  al.:	  Role	  of	  prostate	  volume	  in	  the	  early	  detection	  of	  prostate	  cancer	  in	  a	  cohort	  with	  slowly	  increasing	  prostate	  specific	  antigen.	  Yonsei	  Med	  J,	  54:	  1202,	  2013	  61.	   Uzzo,	  R.	  G.,	  Wei,	  J.	  T.,	  Waldbaum,	  R.	  S.	  et	  al.:	  The	  influence	  of	  prostate	  size	  on	  cancer	  detection.	  Urology,	  46:	  831,	  1995	  62.	   Pierorazio,	  P.	  M.,	  Walsh,	  P.	  C.,	  Partin,	  A.	  W.	  et	  al.:	  Prognostic	  Gleason	  grade	  grouping:	  data	  based	  on	  the	  modified	  Gleason	  scoring	  system.	  BJU	  Int,	  111:	  753,	  2013	  63.	   Muller,	  R.	  L.,	  Faria,	  E.	  F.,	  Carvalhal,	  G.	  F.	  et	  al.:	  Association	  between	  family	  history	  of	  prostate	  cancer	  and	  positive	  biopsies	  in	  a	  Brazilian	  screening	  program.	  World	  J	  Urol,	  31:	  1273,	  2013	  64.	   Faria,	  E.	  F.,	  Carvalhal,	  G.	  F.,	  Vieira,	  R.	  A.	  et	  al.:	  Program	  for	  prostate	  cancer	  screening	  using	  a	  mobile	  unit:	  results	  from	  Brazil.	  Urology,	  76:	  1052,	  2010	  65.	   Johnstone,	  P.	  A.,	  Kane,	  C.	  J.,	  Sun,	  L.	  et	  al.:	  Effect	  of	  race	  on	  biochemical	  disease-­‐free	  outcome	  in	  patients	  with	  prostate	  cancer	  treated	  with	  definitive	  radiation	  therapy	  in	  an	  equal-­‐access	  health	  care	  system:	  radiation	  oncology	  report	  of	  the	  Department	  of	  Defense	  Center	  for	  Prostate	  Disease	  Research.	  Radiology,	  225:	  420,	  2002	  66.	   Fowler,	  J.	  E.,	  Jr.,	  Terrell,	  F.:	  Survival	  in	  blacks	  and	  whites	  after	  treatment	  for	  localized	  prostate	  cancer.	  J	  Urol,	  156:	  133,	  1996	  67.	   Roach,	  M.,	  3rd,	  Lu,	  J.,	  Pilepich,	  M.	  V.	  et	  al.:	  Race	  and	  survival	  of	  men	  treated	  for	  prostate	  cancer	  on	  radiation	  therapy	  oncology	  group	  phase	  III	  randomized	  trials.	  J	  Urol,	  169:	  245,	  2003	  68.	   Hamilton,	  R.	  J.,	  Aronson,	  W.	  J.,	  Presti,	  J.	  C.,	  Jr.	  et	  al.:	  Race,	  biochemical	  disease	  recurrence,	  and	  prostate-­‐specific	  antigen	  doubling	  time	  after	  radical	  prostatectomy	  :	  results	  from	  the	  SEARCH	  database.	  Cancer,	  2007	  69.	   Yanke,	  B.	  V.,	  Carver,	  B.	  S.,	  Bianco,	  F.	  J.,	  Jr.	  et	  al.:	  African-­‐American	  race	  is	  a	  predictor	  of	  prostate	  cancer	  detection:	  incorporation	  into	  a	  pre-­‐biopsy	  nomogram.	  BJU	  Int,	  98:	  783,	  2006	  70.	   Kubricht,	  W.	  S.,	  Kattan,	  M.	  W.,	  Sartor,	  O.	  et	  al.:	  Race	  is	  not	  independently	  associated	  with	  a	  positive	  prostate	  biopsy	  in	  men	  suspected	  of	  having	  prostate	  cancer.	  Urology,	  53:	  553,	  1999	  
  	  
	  	   92  
71.	   Tsivian,	  M.,	  Banez,	  L.	  L.,	  Keto,	  C.	  J.	  et	  al.:	  African-­‐American	  men	  with	  low-­‐grade	  prostate	  cancer	  have	  higher	  tumor	  burdens:	  Results	  from	  the	  Duke	  Prostate	  Center.	  Prostate	  Cancer	  Prostatic	  Dis,	  2012	  72.	   Polednak,	  A.	  P.:	  Black-­‐white	  differences	  in	  tumor	  grade	  (aggressiveness)	  at	  diagnosis	  of	  prostate	  cancer,	  1992-­‐1998.	  Ethn	  Dis,	  12:	  536,	  2002	  73.	   Howlader	  N,	  N.	  A.,	  Krapcho	  M,	  et	  al.:	  SEER	  Cancer	  Statistics	  Review,	  1975-­‐2010,	  National	  Cancer	  Institute.	  Bethesda,	  MD,	  2013	  74.	   Thompson,	  I.	  M.,	  Ankerst,	  D.	  P.,	  Chi,	  C.	  et	  al.:	  Assessing	  prostate	  cancer	  risk:	  results	  from	  the	  Prostate	  Cancer	  Prevention	  Trial.	  J	  Natl	  Cancer	  Inst,	  98:	  529,	  2006	  75.	   Gann,	  P.	  H.,	  Fought,	  A.,	  Deaton,	  R.	  et	  al.:	  Risk	  factors	  for	  prostate	  cancer	  detection	  after	  a	  negative	  biopsy:	  a	  novel	  multivariable	  longitudinal	  approach.	  J	  Clin	  Oncol,	  28:	  1714,	  2010	  76.	   Carver,	  B.	  S.,	  Bozeman,	  C.	  B.,	  Simoneaux,	  W.	  J.	  et	  al.:	  Race	  is	  not	  a	  predictor	  of	  prostate	  cancer	  detection	  on	  repeat	  prostate	  biopsy.	  J	  Urol,	  172:	  1853,	  2004	  77.	   Bennett,	  C.	  L.,	  Ferreira,	  M.	  R.,	  Davis,	  T.	  C.	  et	  al.:	  Relation	  between	  literacy,	  race,	  and	  stage	  of	  presentation	  among	  low-­‐income	  patients	  with	  prostate	  cancer.	  J	  Clin	  Oncol,	  16:	  3101,	  1998	  78.	   U	  S	  Preventive	  Services	  Task	  Force:	  Screening	  for	  Prostate	  Cancer:	  Final	  Recommendation	  Statement.	  AHRQ	  Publication	  No.	  12-­‐05160-­‐EF-­‐2.	  In:	  Ann	  Intern	  Med,	  2012;22	  May	  ed,	  July	  2012	  79.	   Carter	  BH,	  A.	  P.,	  Barry	  MJ,	  et	  al.:	  Early	  Detection	  of	  Prostate	  Cancer:	  AUA	  Guideline,	  2013	  80.	   Du,	  X.	  L.,	  Fang,	  S.,	  Coker,	  A.	  L.	  et	  al.:	  Racial	  disparity	  and	  socioeconomic	  status	  in	  association	  with	  survival	  in	  older	  men	  with	  local/regional	  stage	  prostate	  carcinoma:	  findings	  from	  a	  large	  community-­‐based	  cohort.	  Cancer,	  106:	  1276,	  2006	  81.	   Hsing,	  A.	  W.,	  Chokkalingam,	  A.	  P.:	  Prostate	  cancer	  epidemiology.	  Front	  Biosci,	  
11:	  1388,	  2006	  82.	   Gaston,	  K.	  E.,	  Pruthi,	  R.	  S.:	  Racial	  differences	  in	  prostate	  cancer.	  N	  C	  Med	  J,	  67:	  130,	  2006	  
  	  
	  	   93  
83.	   Pow-­‐Sang,	  M.,	  Destefano,	  V.,	  Astigueta,	  J.	  C.	  et	  al.:	  Prostate	  cancer	  in	  Latin	  America.	  Actas	  Urol	  Esp,	  33:	  1057,	  2009	  84.	   Schmidt,	  M.	  I.,	  Duncan,	  B.	  B.,	  Azevedo	  e	  Silva,	  G.	  et	  al.:	  Chronic	  non-­‐communicable	  diseases	  in	  Brazil:	  burden	  and	  current	  challenges.	  Lancet,	  
377:	  1949,	  2011	  85.	   National	  Cancer	  Institute:	  Center	  for	  Global	  Health:	  US-­‐LA	  CRN	  Partner:	  Brazil.	  Bethesda	  MD,	  2012	  86.	   Center,	  M.	  M.,	  Jemal,	  A.,	  Lortet-­‐Tieulent,	  J.	  et	  al.:	  International	  variation	  in	  prostate	  cancer	  incidence	  and	  mortality	  rates.	  Eur	  Urol,	  61:	  1079,	  2012	  87.	   Ramsbottom-­‐Lucier,	  M.,	  Emmett,	  K.,	  Rich,	  E.	  C.	  et	  al.:	  Hills,	  ridges,	  mountains,	  and	  roads:	  geographical	  factors	  and	  access	  to	  care	  in	  rural	  Kentucky.	  J	  Rural	  Health,	  12:	  386,	  1996	  88.	   Fitzpatrick,	  A.	  L.,	  Powe,	  N.	  R.,	  Cooper,	  L.	  S.	  et	  al.:	  Barriers	  to	  health	  care	  access	  among	  the	  elderly	  and	  who	  perceives	  them.	  Am	  J	  Public	  Health,	  94:	  1788,	  2004	  89.	   Currie,	  J.:	  Healthy,	  Wealthy,	  and	  Wise:	  Socioeconomic	  Status,	  Poor	  Health	  in	  Childhood,	  and	  Human	  Capital	  Development.	  J	  Econ	  Lit,	  47:	  87,	  2009	  90.	   Reyes-­‐Ortiz,	  C.	  A.,	  Camacho,	  M.	  E.,	  Amador,	  L.	  F.	  et	  al.:	  The	  impact	  of	  education	  and	  literacy	  levels	  on	  cancer	  screening	  among	  older	  Latin	  American	  and	  Caribbean	  adults.	  Cancer	  Control,	  14:	  388,	  2007	  91.	   Jemal,	  A.,	  Center,	  M.	  M.,	  DeSantis,	  C.	  et	  al.:	  Global	  patterns	  of	  cancer	  incidence	  and	  mortality	  rates	  and	  trends.	  Cancer	  Epidemiol	  Biomarkers	  Prev,	  19:	  1893,	  2010	  92.	   Clegg,	  L.	  X.,	  Reichman,	  M.	  E.,	  Miller,	  B.	  A.	  et	  al.:	  Impact	  of	  socioeconomic	  status	  on	  cancer	  incidence	  and	  stage	  at	  diagnosis:	  selected	  findings	  from	  the	  surveillance,	  epidemiology,	  and	  end	  results:	  National	  Longitudinal	  Mortality	  Study.	  Cancer	  Causes	  Control,	  20:	  417,	  2009	  93.	   Almeida-­‐Filho,	  N.:	  Higher	  education	  and	  health	  care	  in	  Brazil.	  Lancet,	  377:	  1898,	  2011	  94.	   Albano,	  J.	  D.,	  Ward,	  E.,	  Jemal,	  A.	  et	  al.:	  Cancer	  mortality	  in	  the	  United	  States	  by	  education	  level	  and	  race.	  J	  Natl	  Cancer	  Inst,	  99:	  1384,	  2007	  
  	  
	  	   94  
95.	   Barros,	  M.	  B.,	  Francisco,	  P.	  M.,	  Lima,	  M.	  G.	  et	  al.:	  Social	  inequalities	  in	  health	  among	  the	  elderly.	  Cad	  Saude	  Publica,	  27	  Suppl	  2:	  S198,	  2011	  96.	   Seal,	  M.	  D.,	  Pond,	  G.R.,	  Wilkieson,	  T.J.,	  Hotte,	  S.J.:	  Effect	  of	  geographic	  distance	  from	  a	  cancer	  centre	  on	  choice	  of	  systemic	  therapy	  in	  metastatic	  colorectal	  cancer:	  travel	  time	  and	  distance	  may	  affect	  patient	  decisions.	  Oncology	  Exchange,	  10:	  e8,	  2010	  97.	   Katirai,	  M.:	  Access	  to	  Healthcare	  and	  Colorectal	  Cancer	  in	  Kentucky.	  International	  Journal	  of	  Humanities	  and	  Social	  Science,	  1:	  27,	  2011	  98.	   Patel,	  A.	  R.,	  Jones,	  J.	  S.:	  Optimal	  biopsy	  strategies	  for	  the	  diagnosis	  and	  staging	  of	  prostate	  cancer.	  Curr	  Opin	  Urol,	  19:	  232,	  2009	  99.	   Varmus,	  H.,	  Trimble,	  E.	  L.:	  Integrating	  cancer	  control	  into	  global	  health.	  Sci	  Transl	  Med,	  3:	  101cm28,	  2011	  100.	   Wells,	  T.	  S.,	  Bukowinski,	  A.	  T.,	  Smith,	  T.	  C.	  et	  al.:	  Racial	  differences	  in	  prostate	  cancer	  risk	  remain	  among	  US	  servicemen	  with	  equal	  access	  to	  care.	  Prostate,	  
70:	  727,	  2010	  101.	   Shriver,	  M.	  D.,	  Parra,	  E.	  J.,	  Dios,	  S.	  et	  al.:	  Skin	  pigmentation,	  biogeographical	  ancestry	  and	  admixture	  mapping.	  Hum	  Genet,	  112:	  387,	  2003	  102.	   Carpenter,	  W.	  R.,	  Beskow,	  L.	  M.,	  Blocker,	  D.	  E.	  et	  al.:	  Towards	  a	  more	  comprehensive	  understanding	  of	  cancer	  burden	  in	  North	  Carolina:	  priorities	  for	  intervention.	  N	  C	  Med	  J,	  69:	  275,	  2008	  103.	   Porterfield,	  D.,	  Knight,	  K.:	  Running	  the	  Numbers:	  A	  Periodic	  Feature	  to	  Inform	  North	  Carolina	  Healthcare	  Professionals	  about	  Current	  Topics	  in	  Health	  Statistics.	  NC	  Med	  J	  67,	  2006	  104.	   Nixon,	  R.	  G.,	  Meyer,	  G.	  E.,	  Brawer,	  M.	  K.:	  Differences	  in	  prostate	  size	  between	  patients	  from	  University	  and	  Veterans	  Affairs	  Medical	  Center	  populations.	  Prostate,	  38:	  144,	  1999	  105.	   Warren,	  J.	  L.,	  Klabunde,	  C.	  N.,	  Schrag,	  D.	  et	  al.:	  Overview	  of	  the	  SEER-­‐Medicare	  data:	  content,	  research	  applications,	  and	  generalizability	  to	  the	  United	  States	  elderly	  population.	  Med	  Care,	  40:	  IV,	  2002	  
  	  
	  	   95  
106.	   Boyko,	  E.	  J.,	  Koepsell,	  T.	  D.,	  Gaziano,	  J.	  M.	  et	  al.:	  US	  Department	  of	  Veterans	  Affairs	  medical	  care	  system	  as	  a	  resource	  to	  epidemiologists.	  Am	  J	  Epidemiol,	  
151:	  307,	  2000	  107.	   Zullig,	  L.	  L.,	  Jackson,	  G.	  L.,	  Dorn,	  R.	  A.	  et	  al.:	  Cancer	  incidence	  among	  patients	  of	  the	  U.S.	  Veterans	  Affairs	  Health	  Care	  System.	  Mil	  Med,	  177:	  693,	  2012	  108.	   Rapiti,	  E.,	  Fioretta,	  G.,	  Schaffar,	  R.	  et	  al.:	  Impact	  of	  socioeconomic	  status	  on	  prostate	  cancer	  diagnosis,	  treatment,	  and	  prognosis.	  Cancer,	  115:	  5556,	  2009	  109.	   Ward,	  E.,	  Jemal,	  A.,	  Cokkinides,	  V.	  et	  al.:	  Cancer	  disparities	  by	  race/ethnicity	  and	  socioeconomic	  status.	  CA	  Cancer	  J	  Clin,	  54:	  78,	  2004	  110.	   Jordan,	  H.,	  Roderick,	  P.,	  Martin,	  D.	  et	  al.:	  Distance,	  rurality	  and	  the	  need	  for	  care:	  access	  to	  health	  services	  in	  South	  West	  England.	  Int	  J	  Health	  Geogr,	  3:	  21,	  2004	  111.	   Holmes,	  J.	  A.,	  Carpenter,	  W.	  R.,	  Wu,	  Y.	  et	  al.:	  Impact	  of	  distance	  to	  a	  urologist	  on	  early	  diagnosis	  of	  prostate	  cancer	  among	  black	  and	  white	  patients.	  J	  Urol,	  
187:	  883,	  2012	  112.	   Koka,	  V.	  K.,	  Potti,	  A.,	  Fraiman,	  G.	  N.	  et	  al.:	  An	  epidemiological	  study	  evaluating	  the	  relationship	  of	  distance	  from	  a	  tertiary	  care	  cancer	  center	  to	  early	  detection	  of	  colorectal	  carcinoma.	  Anticancer	  Res,	  22:	  2481,	  2002	  113.	   Harris,	  R.,	  Leininger,	  L.:	  Preventive	  care	  in	  rural	  primary	  care	  practice.	  Cancer,	  72:	  1113,	  1993	  114.	   Roetzheim,	  R.	  G.,	  Pal,	  N.,	  Tennant,	  C.	  et	  al.:	  Effects	  of	  health	  insurance	  and	  race	  on	  early	  detection	  of	  cancer.	  J	  Natl	  Cancer	  Inst,	  91:	  1409,	  1999	  115.	   Bao,	  Y.,	  Fox,	  S.	  A.,	  Escarce,	  J.	  J.:	  Socioeconomic	  and	  racial/ethnic	  differences	  in	  the	  discussion	  of	  cancer	  screening:	  "between-­‐"	  versus	  "within-­‐"	  physician	  differences.	  Health	  Serv	  Res,	  42:	  950,	  2007	  	  
 
